**Study of the use of anti-depressants for depression in dementia: the HTA-SADD Trial - a multicentre randomised double-blind, placebo-controlled trial of the clinical and cost-effectiveness of sertraline and mirtazapine**

Sube Banerjee

Jennifer Hellier

Renee Romeo

Michael Dewey

Martin Knapp

Clive Ballard

Robert Baldwin

Peter Bentham

Chris Fox

Clive Holmes

Cornelius Katona

Claire Lawton

James Lindesay

Gill Livingston

Niall McCrae

Esme Moniz-Cook

Joanna Murray

Shirley Nurock

Martin Orrell

John O’Brien

Michaela Poppe

Alan Thomas

Rebecca Walwyn

Kenneth Wilson

Alistair Burns

**Corresponding Author -** Professor Sube Banerjee, PO26 Section of Mental Health and Ageing, Institute of Psychiatry, King’s College London, De Crespigny Park, London SE5 8AF.Tel: 020 7848 0012 email sube.banerjee@kcl.ac.uk

**Competing interests –** SB has received consultancy and speaker fees, research funding and educational support from pharmaceutical companies making anti-depressants and anti-dementia drugs and been employed by the Department of Health.

**Author affiliations**

Sube Banerjee MDa

Jennifer Hellier MScb

Michael Dewey PhDa

Renee Romeo PhDa

Clive Ballard MDc

Robert Baldwin MDd

Peter Bentham MRCPsyche

Chris Fox MDf

Clive Holmes PhDg

Cornelius Katona MDh

Martin Knapp PhDa

Claire Lawton FRCPsychi

James Lindesay DMj

Gill Livingston MDh

Niall McCrae PhDa

Esme Moniz-Cook PhDk

Joanna Murray MAa

Shirley Nurock MScl

Martin Orrell PhDh

John O’Brien DMm

Michaela Poppe PhDa

Alan Thomas PhDm

Rebecca Walwyn PhDb

Kenneth Wilson MDn

Alistair Burns MDd

a King’s College London, Institute of Psychiatry, Health Services and Population Research Department

b King’s College London, Mental Health and Neuroscience Clinical Trials Unit

c King’s College London, Wolfson Centre for Age-Related Disease

d Department of Community Based Medicine, University of Manchester

e Department of Psychiatry, University of Birmingham

f School of Medicine, University of East Anglia

g Department of Psychiatry, University of Southampton

h Department of Mental Health Sciences, University College London

i Department of Psychiatry, University of Cambridge

j Department of Psychiatry, University of Leicester

k Institute of Rehabilitation, Hull York Medical School

l Alzheimer’s Society, Research Network Volunteer

m Institute for Ageing and Health, Newcastle University

n Department of Psychiatry, Liverpool University

**TABLE OF CONTENTS**

 **Page**

List of abbreviations 4

Executive Summary 5

Chapter 1: Introduction 12

Chapter 2: Method 20

Chapter 3: Results 29

Chapter 4: Discussion 51

Chapter 5: Conclusion 57

Chapter 6: Acknowledgements 60

Chapter 7: References 63

Appendix: Trial Protocol 70

**LIST OF ABBREVIATIONS**

|  |  |
| --- | --- |
| AD | Alzheimer’s Disease |
| AS | Alzheimer’s Society |
| BADL | Bristol Activities of Daily Living |
| BPSD | Behavioural and Psychological Symptoms of Dementia |
| CEAC | Cost-Effectiveness Acceptability Curves |
| CI | Confidence Interval |
| CONSORT | Consolidated Standards of Reporting Trials |
| CSDD | Cornell Scale for Depression in Dementia |
| CSRI | Client Service Receipt Inventory |
| DEMQOL | Dementia Quality of Life |
| DeNDRoN | Dementia and Neurodegenerative Disease Research Network |
| DIADS | Depression in Alzheimer’s Disease Study |
| DMEC | Data Monitoring Committee |
| DSM | Diagnostic & Statistical Manual |
| ENT | Ear, Nose & Throat  |
| EQ5D | EuroQol version 5D |
| GHQ-12 | General Health Questionnaire version 12 |
| GP | General Practitioner |
| HTA | Health Technology Assessment |
| ICER | Incremental Cost Effectiveness Ratio |
| MH&N CTU | Mental Health & Neurosciences Clinical Trials Unit  |
| MHRN | Mental Health Research Network |
| MMSE | Mini-Mental State Examination |
| NASSA | Noradrenergic and Specific Serotonergic Antidepressant |
| NB | Net Benefit |
| NHS | National Health Service |
| NICE/SCIE | National Institute for Health and Clinical Excellence/ Social Care Institute for Excellence |
| NIHR | National Institute for Health Research |
| NINCDS-ADRDA | National Institute of Neurological and Communicative Diseases andStroke/Alzheimer's Disease and Related Disorders Association |
| NPI | Neuropsychiatric Inventory |
| OR | Odds Ratio |
| QALY | Quality Adjusted Life Years |
| QRD | Quality Research in Dementia |
| RCT | Randomised Controlled Trial |
| SADD | Study of Antidepressants for Depression in Dementia |
| SD | Standard Deviation |
| SE | Standard Error |
| SES | Standardised Effect Size |
| SF-12 | Short Form 12 Health Survey |
| SPSS | Statistical Package for the Social Sciences |
| SSRI | Selective Serotonin Reuptake Inhibitor |
| TCA | Tricyclic Antidepressant |
| TSC | Trial Steering Committee |
| UK | United Kingdom |
| VAS | Visual Analogue Scale |

|  |
| --- |
| **Objective/Objectives** |
| Depression is common in dementia causing considerable distress, and other negative impacts. Treating it is a clinical priority but the evidence base is sparse and equivocal. This trail aimed *t*o determine clinical effectiveness of sertraline and mirtazapine in reducing depression 13 weeks post-randomisation compared with placebo. |
| **Design** |
| Multi-centre parallel group double-blind placebo-controlled RCT of the clinical effectiveness of sertraline and mirtazapine with 13 and 39 week follow up. |
| **Setting** |
| From nine English old age psychiatry services. |
| **Participants** |
| A pragmatic trial, eligibility: probable or possible Alzheimer's Disease, depression (4+ weeks), and Cornell Scale for Depression in Dementia (CSDD) score of 8+. Exclusions: clinically too critical (eg suicide risk); contra-indication to medication; taking antidepressants; in another trial; and having no carer. |
| **Interventions** |
| (1) Sertraline, (2) mirtazapine, and (3) placebo, all with normal care. Target doses: 150mg sertraline or 45mg mirtazapine daily. |
| **Main outcome measures** |
| *Outcome* – CSDD score.*Randomisation* - Allocated 1:1:1 through Trials Unit, independently of trial team. Stratified block randomisation by centre with randomly varying block sizes; computer-generated randomisation. *Blinding* - Double-blind, medication and placebo identical for each antidepressant. Referring clinicians, research workers, participants and pharmacies were blind. Statisticians blind until analyses completed. |
| **Results** |
| *Numbers randomised* - 326 participants randomised (111 placebo, 107 sertraline, 108 mirtazapine).*Outcome* - Differences in CSDD at 13 weeks from an adjusted linear mixed model: mean difference (95%CI) placebo/sertraline 1.17 (-0.23 to 2.78, p=0.102); placebo/mirtazapine 0.01 (-1.37 to 1.38, p=0.991); and mirtazapine/sertraline 1.16 (-0.27 to 2.60, p=0.112).*Harms* - Placebo group had fewer adverse reactions (29/111, 26%) than sertraline (46/107, 43%) or mirtazapine (44/108, 41%; p=0.017); 39 week mortality equal, five deaths in each group. |
| **Conclusion/conclusions** |
| This is a trial with negative findings but important clinical implications. The data suggest that the antidepressants tested, given with normal care, are not clinically effective (compared with placebo) for clinically significant depression in Alzheimer’s disease. This implies a need to change current practice of antidepressants being the first line treatment of depression in Alzheimer’s disease. |
| **Source of funding** |
| This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. [x], No. [x] *(to be completed by the publisher)*. See the HTA programme website for further project information. |

**EXECUTIVE SUMMARY**

**Background**

Dementia is one of the most common and serious disorders in later life. Worldwide it affects 35 million, and this will treble by 2050.In the UK there are 750,000 people with dementia and 200,000 new cases every year. It causes irreversible decline in global intellectual, social and physical functioning. In the UK dementia costs around £17 billion per year; worldwide, its annual cost is $600 billion with this set to at least triple in the next 20 years. The negative impacts of dementia on those with the disorder, in terms of deteriorating function, and on carers are profound. Dementia has a devastating impact across culture, gender, ethnicity and class. The need to improve care for people with dementia is a policy priority.

Depression is common in dementia with prevalence over 20%, causing distress, reducing quality of life, exacerbating cognitive and functional impairment, increasing mortality, and increasing carer stress and depression. Treating depression is therefore a key clinical priority to improve the well-being, quality of life and level of function of people with Alzheimer’s disease.

The Cochrane review *Antidepressants for treating depression in dementia* identified only three studies, comprising 107 subjects that had data that could be subject to a meta-analysis of efficacy. It concluded that, despite its clinical seriousness, there was only weak evidence of the effectiveness of antidepressants in dementia. Two studies used tricyclics “drugs not commonly used in this population” (because anticholinergic side effects may negatively affect cognition, and cardiac side effects); only one used the most commonly used class (SSRIs). None covered newer classes of antidepressants and all were of short duration. Subsequently, the DIADS-II study compared 67 people prescribed sertraline, with 64 given placebo. In contrast to the DIADS study included in the Cochrane review, they found no benefit whatsoever of sertraline.

Despite the equivocal evidence, current practice is to use antidepressants, often sertraline, as a first line treatment for depression in dementia. Given the limited evidence in this clinically important area, the Health Technology Assessment (HTA) Programme of the UK NIHR prioritised antidepressant treatment of depression in dementia as an area for primary research. They commissioned the study reported here to fill gaps in the evidence base definitively and enable the formulation of good quality guidance on care for people with dementia and their carers.

**Trial design**

Multi-centre parallel group double-blind placebo-controlled RCT of the clinical effectiveness of sertraline and mirtazapine with 13 and 39 week follow up.

**Methods**

**Participants** This was a pragmatic trial, with inclusion criteria designed to mirror clinical practice closely. Those eligible met NINCDS/ADRDA criteria for probable or possible Alzheimer's Disease and co-existing depression of at least four weeks duration with a CSDD of 8+. The only exclusions were: too critical for randomisation (eg suicide risk); absolute contra-indication to trial medications; currently taking antidepressants; being in another trial; and having no informant to give collateral information.Participants were recruited from community old age psychiatry services in nine English centres.

**Interventions:** There were three groups: (1) sertraline, (2) mirtazapine, and (3) placebo, all with normal clinical care. The target dose was for all participants was 150mg sertraline or 45mg mirtazapine per day.

**Primary outcomes:** Depression in dementia, measured by CSDD, and costs measured by the Client Service Receipt Inventory (CSRI) at 13 weeks.

# Secondary Outcomes and moderators: These included: disease-specific health related quality of life (DEMQOL and DEMQOL-Proxy); generic quality of life (EQ-5D interview administered to carer); withdrawal from treatment; cognitive impairment (Mini Mental State Examination MMSE); medication adherence; adverse events; carer mental health (General Health Questionnaire GHQ-12); carer quality of life (SF-12v2); and carer burden (Zarit Scale); behavioural disorder (Neuropsychiatric Inventory NPI); and (at baseline) a dementia vascularity index (modified Hachinski scale).

**Sample size:** Initially a sample size of 507 was calculated to provide 90% power to detect a 2 point CSDD difference (SD 5; SES 0.4) for the sertraline/placebo and the mirtazapine/placebo comparisons at 13 weeks, and 86% power at 39 weeks.

**Change to protocol:** Due to a call for extra funding following slower recruitment than predicted, the sample size needed for the trial was reassessed by statistical review by the Data Monitoring and Ethics committee (DMEC) when there were 75 subjects available with 13 week follow-up data. The parameters of the sample size calculation were not changed, but the new target was calculated on the basis of reported values with greater precision than pre-study assumptions. An extended recruitment was agreed with a revised target of 339 participants.

**Randomisation:** Participants were allocated to placebo, sertraline or mirtazapine (1:1:1) through the Clinical Trials Unit (CTU) after baseline assessment and obtaining consent. The CTU database programmer independently undertook treatment allocation. Random allocation was stratified by centre and done with a computer-generated randomisation sequence with randomly varying block sizes.

**Blinding:** The trial was double-blind with medication and placebo identical in appearance for each antidepressant. Referring clinicians and research workers completing assessments were kept blind to group allocation as were patients and pharmacies. Statisticians were blind to group identity until after the analyses were completed.

**Statistical methods:** Significance was tested at 5%. Analyses were pragmatic, based an intention to treat. CSDD differences between treatment groups (sertraline/placebo and mirtazapine/placebo), were estimated with mixed linear regression models. Covariates were treatment group, baseline CSDD score, time and the stratification factor, centre. A time-by-treatment interaction term was included to allow estimates at the individual time points to be summarised. The model for the CSDD incorporated random intercepts by participant. Model assumptions were checked by use of diagnostic plots. We compared categorical variables by use of Fisher’s exact test. We analysed secondary outcomes with mixed linear regression models with random participant intercepts and a time-by-treatment interaction term; covariates in the model were treatment group, baseline value of outcome, time, and treatment centre. NPI analyses utilised the generalised linear model framework; specifying a negative binomial distribution and logit link.

**Health Economics method:** The primary economic evaluation was a cost-effectiveness analysis comparing differences in treatment costs for patients receiving sertraline, mirtazapine or placebo with CSDD score, over 0-13 weeks and 0-39 weeks. The secondary analysis was a cost-utility analysis using quality-adjusted life years (QALYs) computed from the EQ-5D and societal weights. Both the primary and secondary economic evaluations were undertaken from the perspective of (a) health and social care agencies and (b) health, social care agencies and informal carers. Health and social care costs for 0-13 months and 0-39 months (and health, social care and costs of informal care costs for the parallel analysis from the broader perspective for the same time periods) were regressed in turn on treatment allocation, baseline cost, baseline CSDD and centre. To mitigate the effects of skew-ness, non-parametric bootstrapping methods were used to estimate 95%CIs for mean costs. Estimates of bootstrapped mean cost and effectiveness were used to estimate an incremental cost-effectiveness ratio (ICER) for each analysis. The value of health effects was then expressed in terms of quality-adjusted life years (QALYs). Uncertainty around the costs and effectiveness estimates was addressed by plotting cost-effectiveness acceptability curves (CEAC).

**Results**

**Trial Recruitment:** 664 individuals were screened; 326 (49%) were randomised; 111 to placebo, 107 to sertraline and 108 to mirtazapine. Groups were evenly matched, the majority of participants were female, with mean age 79 years; 146 (45%) were married.

**Outcomes and estimation - primary outcome: CSDD** The absolute change from baseline at 13 weeks was greatest for placebo -5.6 (SD 4.7), compared to -3.9 (5.1) for sertraline and -5.0 (4.9) for mirtazapine. This was difference was maintained through to 39 weeks, change scores of -4.8 (5.5) for placebo, -4.0 (5.2) for sertraline and -5.0 (6.1) for mirtazapine. The results from the linear mixed modelling, after adjusting for baseline depression and centre made clear that there was no evidence of a difference between sertraline and placebo or mirtazapine and placebo, on the CSDD score at 13 or 39 weeks. This analysis provides robust evidence of an absence of clinical effectiveness of the antidepressants tested here compared with placebo.

**Secondary outcomes:** There were fewer neuropsychiatric symptoms and higher carer-rated health related quality of life (HRQL) scores (DEMQOL-Proxy) in participants given mirtazapine compared with sertraline; these differences did not persist to 39 weeks. Carers whose relatives were receiving placebo had higher HRQL scores at 13 weeks (SF-12 mental component score) and higher mental health scores (GHQ-12) than did those on sertraline. Carers of participants in the mirtazapine group had HRQL scores (SF-12 mental component score) at 13 weeks than did those in the sertraline group.

**Safety data:** 119 participants reported 240 adverse reactions. 29/111 (26%) in the placebo group had adverse reactions, compared with 46/107 (43%) in the sertraline group (p=0·010) and 44/108 (41%) in the mirtazapine group (p=0·031; overall p-value for placebo vs either drug =0·017). Overall, the number of serious adverse events reported did not differ between groups but more of these events were severe in those on antidepressants compared with placebo (p=0·003). Mortality did not differ between groups (five deaths in each group by 39 weeks).

**Economic analyses:** In the 0-13 week period, there were no differences in service use between the treatment groups reaching statistical significance. However, taking the whole 0-39 week period, it was striking that the mean number of hours per week spent by unpaid carers caring for patients in the placebo-treated group and the sertraline group were almost twice that for patients in the mirtazapine-treated group. This difference in unpaid carer time between the placebo and mirtazapine-treated group was statistically significant at the 5% level. On the secondary measure of outcome, the mean QALY gain at 39 weeks between placebo and sertraline was 0.03 (-0.09 to 0.03); between placebo and mirtazapine 0.05 (-0.10 to 0.01); and between mirtazapine and sertraline 0.02 (-0.03 to 0.07). There were no statistically significant differences in either the primary or secondary measure of outcome between groups at 13 or 39 weeks. After adjustment for baseline costs, CSDD score at baseline and site, there were no statistically significant differences in health and social care costs (or health, social care and unpaid carer costs) in any pairwise comparison in either time period. Mirtazapine had a low likelihood (around 30%) of being more cost-effective than placebo if society were not willing to pay anything for a unit improvement in the CSDD depression score with this rising to 80% if society were willing to pay £5,000 for a unit improvement in CSDD score. In the secondary economic evaluation, where costs were considered alongside QALYs, mirtazapine was 89% likely to be more cost-effective than placebo even if society was willing to pay nothing for a QALY gain.

**Conclusions**

This is a trial with negative findings but important clinical implications. The data suggest that the antidepressants tested, given with normal care, are not clinically effective (compared with placebo) for clinically significant depression in Alzheimer’s disease. The data do not support the use of antidepressants as the first line treatment of depression in Alzheimer’s disease.

As far as we are aware this is the first study to explore the cost-effectiveness of mirtazapine and sertraline in treating depression in dementia. Our results show that mirtazapine and sertraline are not cost-effective compared to placebo as a treatment for depression in dementia when looking at the primary outcome of change in depressive symptoms. However Mirtazapine did halve unpaid carer time and therefore carer costs. So, when costs were considered alongside QALY gains, a different picture emerged. Mirtazapine had the highest likelihood of cost-effectiveness compared to sertraline and placebo.

We considered possible reasons for the finding that mirtazapine treatment had a good chance of being cost-effective compared to placebo or sertraline when the outcome under consideration is the QALY. The trend towards lower incremental costs for mirtazapine was driven by the statistically significantly lower unpaid carer inputs. The small improvements in quality of life for mirtazapine relative to the other treatments also contributed to the cost-effectiveness result, and can perhaps be mediated plausibly via the putative ability of mirtazapine to ameliorate sleep disturbances and anxiety. Improvements in sleep could potentially improve life quality and therefore patient-reported EQ-5D scores; they could also release carer time directly and so ameliorate an important source of carer distress. In this way mirtazapine might have a general effect, beneficial for both the patient and the carer, without exerting a specific antidepressant effect. The potential positive effects of mirtazapine seem to act more in the realm of general behavioural and psychological symptoms in dementia (BPSD) than depression *per se*.

The data from this study provide evidence to support antidepressants not being prescribed as a first line treatment for people with depression in Alzheimer’s disease who are referred to old age psychiatry, for all but the most critical of cases (by reason for example of self-harm or other risk), as many cases will resolve with usual care and without sertraline or mirtazapine. Alternatives to antidepressants include the stepped care, with ‘watchful waiting’ that is advocated currently as best practice for the general treatment of depression (without dementia) in the community. The first step is provision of “low-intensity psychosocial interventions” with more complex psychosocial interventions an alternative to antidepressants at the next stage of severity. Those recruited into the trial will have received non-drug ‘treatment as usual’ provided by the community mental health teams to whom they were referred. This will have included a broad range of supportive and problem-solving interventions, commonly delivered by a community psychiatric nurse, often in their own household. This will have focussed on problems encountered by the person with dementia and the carer, covering aspects of dementia as well depression and ranging in intensity from low to high as needed. Identifying which components of ‘usual care’ may be effective is an important area for future research. Other explanations for the observed changes for all cases over time include regression to the mean, and Hawthorne and placebo effects. As we find no evidence to support use of antidepressants, it suggests that potential cases might be more appropriately managed by specialist services that are able to offer non-drug interventions for depression, perhaps avoiding the use of medication with potential for adverse reactions.

*EudraCT Number* - 2006-000105-38

**CHAPTER 1: INTRODUCTION**

**Scientific background**

Dementia is one of the most common and serious disorders in later life with a prevalence of 5% and an incidence of 2% per year in the over 65s.1,2 Worldwide it affects 35 million, and this will treble by 2050.3 In the UK there are 750,000 people with dementia currently4 and 200,000 new cases every year. It causes irreversible decline in global intellectual, social and physical functioning. Abnormalities in behaviour, insight and judgement are part of the disorder, as are neuropsychiatric symptoms such as psychosis, anxiety and depression. The economic cost of caring for people with dementia is immense. In the UK the costs of dementia are around £17 billion per year4, greater than stroke (£3 billion), heart disease (£4 billion) and cancer (£2 billion).5 Worldwide, its annual cost is $600 billion, 1% of world GDP,6 and these are set to at least triple in the next 20 years.6,7 The need to improve care for people with dementia is a policy priority.8.9,10,11  More importantly, the negative impacts of dementia on those with the disorder, in terms of deteriorating function, and on carers12,13 are profound. Dementia has a devastating impact across culture, gender, ethnicity and class.

Depression is common in dementia with prevalence over 20%,14,15 causing distress, reducing quality of life, exacerbating cognitive and functional impairment, increasing mortality, and increasing carer stress and depression.16,17,18 Treating depression is therefore a key clinical priority to improve the well-being, quality of life and level of function of people with Alzheimer’s disease.

We searched the PubMed and Cochrane Library databases to March 1, 2011, without language restrictions for full articles reporting randomised controlled trials, systematic reviews, and meta-analyses with the search terms “depression”, “dementia”, “Alzheimer’s disease”, antidepressant”, ”meta-analysis”, and “CSDD”. We excluded trials without recognised depression outcome measures, placebo controls, or specified thresholds for depressive disorder. We identified one Cochrane review19 and three systematic reviews.20,21,22

The Cochrane review completed in July 2002 *Antidepressants for treating depression in dementia*19 identified six studies with 739 subjects meeting inclusion criteria (“all relatively unconfounded, double-blind, randomized trials comparing any antidepressant drug…with placebo, for patients diagnosed as having dementia and diagnosed as having a depression according to established criteria”). Only three studies, comprising 107 subjects, had data that could be subject to a meta-analysis of efficacy. Petracca et al23 studied 24 subjects in a neurological out-patient clinic in Argentina in a double blind placebo controlled crossover trial of clomipramine (a tricyclic antidepressant [TCA]) with two 6 week treatment periods with a 2 week washout period. There was a mean change of -10.7 on the Hamilton depression scale in the intervention group and –4.5 in the control group, an equivocal outcome. Reifler et al24 selected 61 subjects from two university outpatient clinics in an 8 week double blind trial of imipramine (a TCA). The study showed no treatment effect. The third trial included25 was an interim analysis of data on 22 subjects that subsequently were reported fully in Lyketsos et al26. These final data from DIADS were not available to the Cochrane review. In the final study 44 subjects were recruited from a single university out-patient clinic into a 12 week double-blind placebo controlled trial of sertraline (a specific serotonin reuptake inhibitor [SSRI]). An effect size of 0.51 was reported with a mean change of -10.5 on the Hamilton depression scale in the intervention group and –4.5 in the control group and –9.9 and –3.2 in on the Cornell Scale for Depression in Dementia (CSDD27). Other than the further data on the additional 22 cases reported in Lyketsos et al,26 and the groups subsequent DIADS-II study28 which was negative and which is discussed below, we are not aware of any other studies published since that would have met the criteria for inclusion in the Cochrane review.

The Cochrane review concluded that, despite its clinical seriousness, there was only weak evidence of the effectiveness of antidepressants in dementia. Two studies used TCAs “drugs not commonly used in this population” (because anticholinergic side effects may negatively affect cognition, and cardiac side effects); only one used the most commonly used class (SSRIs). None covered newer classes of antidepressants and all were of short duration. Lyketsos et al26 acknowledged the need for research into the efficacy of antidepressants in a wider range of depression type and severity, longer-term treatment, and the comparative efficacy of different classes of antidepressants. They therefore completed a follow up study, the DIADS-II study. This compared 67 people prescribed sertraline with 64 given placebo. In contrast to DIADS, they found no benefit whatsoever of sertraline at 12 or 24 weeks and concluded that this was not a function of depression severity, depression type or severity of dementia.28,29

One systematic review20 used a different quality assessment and included data from five studies of 165 participants, and concluded that antidepressants were better than was placebo for treatment response (odds ratio [OR] 2·32, 95% CI 1·04–5·16) and remission of depression (2·75, 1·13–6·65) with rates of discontinuation equivalent to placebo. This did not include the DIADS-II data. The positive message of the meta-analysis of the 2010 systematic review21 is questionable because, although it includes the DIADS-II data,28,29 it seems to count the data from the first DIADS trial twice (ie, by treating the interim25 and the final trial data26 as separate datasets when the first is a subset of the second). Finally, the 2011 study20 concluded that the efficacy of antidepressants in people with depression and dementia is not established. The reviews and meta-analyses taken together are not conclusive but all reported that limitations of previous trials were their small sizes, low numbers of participants taking drugs that were used in clinical practice, and short follow-up.

It is clear that the subjects recruited into all the trials discussed above were highly selected and so there may be limitations in the generalisability of the data derived from them. One element of this is the severity of depression recruited, with Lyketsos et al26 and Reifler et al24 requiring depression to meet DSM criteria for major depressive episode. Such disorders form only a small proportion of clinically significant depression requiring intervention in older adults in the community.

All of these studies except DIADS-II, were of short duration, and so could not tackle the crucial issue of whether there is longer term benefit associated with antidepressant treatment. It is unclear whether the differential efficacy between the published studies relates to the choice of antidepressant, differences in study design and power or chance variation. Importantly, the literature does indicate that the successful resolution of depression may be associated with cognitive and functional improvements30. There are however several cautions. For example, one study of the tricyclic antidepressant imipramine indicated that active treatment increased cognitive impairment and disability, whilst several studies of falls indicate that most antidepressants increase risk of falling. In addition, there have been safety concerns relating to the SSRI sertraline and gastrointestinal bleeding 31 and the SSRI paroxetine and withdrawal.

Despite the equivocal evidence, current practice is to use antidepressants, often sertraline, as a first line treatment for depression in dementia. The Quality Standards Subcommittee of the American Academy of Neurology32 cited only “moderate clinical certainty” for antidepressants in treating depression in dementia, but concluded that “SSRIs may offer some benefit with greater tolerability”. A UK primary care guideline suggests antidepressants as the only form of management for depression in dementia33 and the UK NICE/SCIE Clinical Guideline on Dementia34 also advocates antidepressants for depression in dementia.

Given limited evidence in this clinically important area, the Health Technology Assessment (HTA) Programme of the UK NIHR prioritised antidepressant treatment of depression in dementia as an area for primary research. They commissioned the study reported here to fill gaps in the evidence base definitively and enable the formulation of good quality guidance on care for people with dementia and their carers.

# Explanation of rationale

# Experimental – Inclusion of an arm of the study using tricyclic antidepressants

As discussed above, there are unanswered questions concerning what class of antidepressant to choose and how long to treat. This trial was designed to attempt provide best-quality data on all these clinically important areas.

One possible area of contention is the appropriateness of including a tricyclic antidepressant (TCA) arm in the trial. This was referred to in the original research brief. Prior to our initial submission we carried out a local consultation with people with dementia, family carers and clinicians in London, Manchester and within the Alzheimer’s Society. The findings of this exercise were clear. Patients, carers and clinicians all believed that it would be unacceptable to randomise people with dementia to medication with a predictable set of negative (anticholinergic eg constipation, increased confusion, blurred vision, low blood pressure, drowsiness) side effects even given the fact that the competing classes of medication had their own profile of side effects.

In addition, clinicians reported to us that their clinical practice was not to use TCAs as a first line treatment for depression in dementia and that they believed people with dementia to be at a higher risk of harm from TCA side effects than people without dementia. They therefore raised questions of the clinical acceptability of a trial that included the possibility of randomisation to a TCA. To be successful we needed a large number of clinical teams to take part in case finding and if the trial were to generate real effectiveness data then these participants needed to be an unbiased sample of all potential prescribers. On these grounds we therefore decided not to include a tricyclic antidepressant arm but instead to compare the clinical and cost-effectiveness (including discontinuation and adverse events) of examples of the two classes of antidepressants most in use.

In the subsequent feedback from the HTA Commissioning Board we were invited to reconsider our decision not to include a TCA arm. We therefore consulted the Alzheimer’s Society Quality Research in Dementia (QRD) Network. This was a panel made up of people with dementia and their carers that advised the UK Alzheimer’s Society (AS) on research issues. The consultation was carried out by the AS Director of Research (Prof Clive Ballard). He consulted regional co-ordinators of the Alzheimer Society’s (QRD) and individual members of the network, representing the views of 45 QRD members; most with experience of caring for someone with dementia who has been treated with antidepressants. The purpose was to inform them about key aspects of the study, in particular whether it was appropriate to include TCAs as one of the treatments. All but one of the people responding strongly expressed the view that TCAs were an inappropriate treatment for people with dementia, describing a number of personal experiences where serious falls, increased confusion, urinary retention and other adverse events had resulted in a serious detrimental impact to the quality of life of the person with dementia.

We also consulted clinicians through the potential collaborating centres more widely and again there was a near unanimous view that it was not clinically supportable to initiate people with depression in dementia on a TCA. They also reported that the existence of such a possibility in randomisation would discourage them from entering patients into the trial. At the very least it was therefore likely that there would be substantial selection bias (both in patient acceptability and clinician referral) introduced by the inclusion of a TCA arm. We therefore decided not to include a TCA arm.

**Experimental – Choice of antidepressants**

The selection of the best candidate antidepressants for this trial is not straightforward. Cost and power considerations dictate that an optimal design should include two active antidepressant treatments and a placebo. There are however several cautions. One previous small RCT has indicated equivocal benefit with the TCA clomipramine,23 but other data indicate marked side effects and exacerbation of disability associated with TCA treatment. For example, one study of the tricyclic antidepressant imipramine, indicated that active treatment increased cognitive impairment and disability,24 whilst several studies of falls indicate that most antidepressants increase falls risk.35 In addition, there have been safety concerns with SSRIs, with respect to withdrawal effects and the potential risk of self-harm.

Within this framework, the choice of specific antidepressant agents required careful consideration. For example, the best evidence of efficacy in people with dementia at the time of the trial design was for the SSRI sertraline since that was the compound used in the original DIADS study.26 But this was a very small trial and other SSRIs such as citalopram have also been reported to be effective in treating depression in later life, including those with dementia, but in less well designed studies.36 Citalopram may have less interactions with other drugs than other SSRIs and people with dementia are usually recipients of polypharmacy. The most effective antidepressant in people without dementia available at that time was probably venlafaxine,37 but there are no RCTs in people with dementia and there are potential concerns regarding side effects in these individuals.38 A newer antidepressant, mirtazapine, appeared to have a good safety profile and a different mode of effect and was becoming widely used in clinical practice to treat depression in people with dementia, but had not been evaluated in an RCT for this indication.

In order to design and cost a trial of this sort there is a need to identify the compounds to be tested. We therefore made the decision that our trial design should include sertraline (the SSRI with the best evidence and which would be off licence by the end of the trial) and mirtazapine (the novel antidepressant with the least safety concerns). The doses chosen reflect common clinical practice for the treatment of depression in dementia and (in the case of sertraline) direct trial evidence,26 with higher doses than those suggested here (ie over 150mg of sertraline or 45mg of mirtazapine) being seen as less appropriate in people with dementia as well as depression.

# Controls – use of placebo

The research brief referred to comparison with standard care. Despite the evidence base, standard care for depression in dementia is the provision of antidepressants with SSRIs the most commonly used drugs.32 Standard secondary care (and it was stipulated in the brief that the study should be people referred to secondary care) is however much more than just medication. It involves a detailed multidisciplinary assessment of the person with dementia and their family carers with the generation of an individualised care package for each, often with continuing monitoring and follow-up.39 We therefore developed a study design whereby all participants receive full standard care with only the antidepressant element subject to investigation against placebo and between classes of compound.

We concluded that at the time of the trial design, that there was little convincing evidence that anti-depressant treatments were more effective than placebo in treating depression in dementia in real-world clinical practice. As discussed above, the data available were generally from small-scale studies of highly selected groups of patients with depression in dementia. The research brief required a trial which could take the evidence base and clinical practice forward significantly. In these circumstances we came to the belief that a placebo group was not just ethical, but essential. If antidepressants were indeed not effective, then the placebo group might do better as they should have had fewer side effects. We carried out a further consultation exercise on the acceptability of the inclusion of a placebo group with local people with dementia, family carers and clinicians. They were supportive of the strategy of using placebo in these circumstances as long as its use was minimised and that the information derived from the trial would yield a definitive answer.

**Run-in period**

One possible element of a trial such as this is the inclusion of a run in period. The potential value of this is to identify a group of people more likely to comply with subsequent data collection (ie to minimise loss to follow-up) and to identify a group of people with depression who are less likely to spontaneously recover.40,41,42 It is also possible that depression scores may be reduced by psychosocial interventions,43 some of which may be provided as part of routine care. The result of these factors is a potentially high placebo response rate in clinical trials. The research brief was clear in its call for an evaluation of antidepressants in routine clinical practice and it is not routine clinical practice to precede the prescription of antidepressants for depression in dementia with a trial of a non-pharmacological treatment such as exercise. Instead we proposed the clinically relevant inclusion criterion for the trial that the depression should have been present for at least 4 weeks.

**Specific Objectives**

The primary objective was to determine the clinical and cost effectiveness of an SSRI (sertraline) and a Noradrenergic and Specific Serotonergic Antidepressant (NASSA, mirtazapine) in reducing depression (measured by CSDD) 13 weeks post randomisation compared with placebo.

Secondary objectives included: clinical effectiveness at 39 weeks; differences in adverse events; other outcomes (eg quality of life, cognition, carer burden, carer quality of life); and the influence of clinical characteristics (eg dementia severity, dementia type, depression type, depression severity, and neuropsychiatric symptoms).

**CHAPTER 2: METHODS**

**Trial design**

A multi-centre parallel group double-blind placebo-controlled RCT of the clinical effectiveness of two antidepressants, mirtazapine with 13 and 39 week follow up (1:1:1 allocation).

**Participants**

**Eligibility**

This was a pragmatic trial, with inclusion criteria designed to mirror clinical practice closely. Those eligible met NINCDS/ADRDA criteria for probable or possible Alzheimer's Disease44 and co-existing depression of at least four weeks duration. A local research worker then assessed their depression severity using the CSDD.27 Those scoring 8+ were eligible for the trial. The only exclusions were: clinically too critical for randomisation (eg suicide risk); absolute contra-indication to trial medications; currently taking antidepressants; being in another trial; and having no family or professional carer to give collateral information.

**Settings and location**

Participants were recruited from community old age psychiatry services in nine English centres (Birmingham, Cambridge, Leicester, Liverpool, Manchester, Newcastle, North London, Southampton, and South London & Kent).

**Interventions**

There were three groups: (1) sertraline, (2) mirtazapine, and (3) placebo, all with normal clinical care. The target dose was for all participants was 150mg sertraline or 45mg mirtazapine per day. Drugs and their placebo were identically presented with participants aiming to take six tablets orally once a day (up to three sertraline 50mgs or sertraline placebo; and up to three mirtazapine 15mgs or mirtazapine placebo).

**Outcomes**

**Co-primary Outcomes**

Depression in dementia, measured by CSDD,27 and costs measured by the Client Service Receipt Inventory (CSRI)45 at 13 weeks.

# Secondary Outcomes and moderators

# These included: disease-specific health related quality of life (DEMQOL and DEMQOL-Proxy);46 generic quality of life (EQ-5D interview administered to carer);47 withdrawal from treatment; cognitive impairment (Mini Mental State Examination MMSE);48 medication adherence; adverse events; carer mental health (General Health Questionnaire GHQ-12)49; carer quality of life (SF-12v2);50 and carer burden (Zarit Scale);51 behavioural disorder (Neuropsychiatric Inventory NPI);52 and (at baseline) a dementia vascularity index (modified Hachinski scale).53

**Data Entry**

The data arising from each baseline or follow-up interview were entered at each centre via the internet using the InferMed Macro electronic data capture system by the researchers as the study proceeded. The data entry system used was Macro version 3.0. Prior to data base lock, all of the primary outcome measures and 10% of all other outcome measures were source data verified. Table 1 summarises the measures that were used at each assessment time point.

***Table 1: Research assessment by time point***

**Sample size**

Initially a sample size of 507 was calculated to provide 90% power to detect a 2 point CSDD difference (standard deviation [sd] 5; SES 0.4) for the sertraline/placebo and the mirtazapine/placebo comparisons at 13 weeks, and 86% power at 39 weeks. This allowed 20% loss to follow-up, correlation between baseline and outcome CSDD ≥ 0.6, and up to 12.5% of participants to either drop-out or drop-in using an analysis of covariance with 2-sided 5% significance levels. This allowed for two-sided 95% confidence intervals for the difference in the proportion of adverse events between the groups of (a clinically significant) 10%.

**Change to protocol**

Due to a call for extra funding following slower recruitment than predicted, the sample size needed for the trial was reassessed by statistical review by the Data Monitoring and Ethics committee when there were 75 subjects available with 13 week follow-up data. The parameters of the sample size calculation were not changed (SD 5; SES 0·4), but the new target was calculated on the basis of reported values that had greater precision than did the pre-study assumptions. An extended recruitment period was agreed with a revised target of 339 participants for the sample (113 in every group). This change involved unmasking of a statistician (Clare Rutterford, Clinical Trials Unit, King’s College London, UK), who was not involved in the final analyses, to the identity of patients in the placebo group.

**Randomisation**

Participants were allocated to placebo, sertraline or mirtazapine (1:1:1) through the Mental Health & Neurosciences Clinical Trials Unit (MH&N CTU) after baseline assessment and obtaining consent. The MH&N CTU database programmer independently undertook treatment allocation. Random allocation was stratified by centre and done with a computer-generated randomisation sequence with randomly varying block sizes (block sizes of 3 or 6). Allocation was physically carried out during working hours Monday to Friday

**Blinding**

The trial was double-blind with medication and placebo identical in appearance for each antidepressant. Referring clinicians and research workers completing baseline and follow-up assessments were kept blind to group allocation as were patients and pharmacies. Statisticians were blind to group identity until after the analyses were completed.

**Statistical methods**

The statistical analysis plan was finalised and approved by the Trial Steering and the Data Monitoring and Ethics Committees. Significance was tested at 5% level for all analyses. Analyses were completed in Stata 11.0. Analyses were pragmatic, based an intention to treat sample.

**Descriptive statistics**

All baseline data were summarised by treatment groups. Only descriptive statistics were utilised, no formal statistical comparisons were undertaken. Continuous variables were reported as means and standard deviations (SD), categorical variables are presented as frequencies (n) and percentages (%).

**The primary analyses**

CSDD differences between treatment groups (sertraline/placebo and mirtazapine/placebo), were estimated with mixed linear regression models. Covariates were treatment group, baseline CSDD score, time and the stratification factor, centre. A time-by-treatment interaction term was included to allow estimates at the individual time points to be summarised. The model for the CSDD incorporated random intercepts by participant. Model assumptions were checked by use of diagnostic plots.

We did modelling with the assumption that data were missing at random, and included predictors of missing data (treatment group and centre) in the modelling. We used a logistic model to assess predictors of missing data (examination of all baseline clinical and demographic variables).

**Secondary Analyses**

We compared categorical variables by use of Fisher’s exact test. We analysed secondary outcomes with mixed linear regression models with random participant intercepts and a time-by-treatment interaction term; covariates in the model were treatment group, baseline value of outcome, time, and treatment centre. The more detailed NPI analyses utilised the generalised linear model framework; specifying a negative binomial distribution and logit link. The modelling was cross sectional at each time point (13 and 39 weeks), covariates in the model were treatment group, baseline value of outcome and treatment centre. All analyses results are summarised at 13 weeks and 39 weeks with two-sided 95% Confidence Intervals (CIs)

**Health Economics – Methods**

**Economic evaluation**

The primary economic evaluation was a cost-effectiveness analysis comparing differences in treatment costs for patients receiving sertraline, mirtazapine or placebo with differences in effectiveness as measured by the primary outcome, total CSDD score, over two time periods: 0-13 weeks and 0-39 weeks. The secondary analysis was a cost-utility analysis using quality-adjusted life years (QALYs) computed from the EQ-5D and societal weights over those same periods. Both the primary and secondary economic evaluations were undertaken from the perspective of (a) health and social care agencies and (b) health, social care agencies and informal carers. A measure of quality of life was appropriate for the secondary analysis as it was recognised that trial medication not only has a potential impact on depressive symptoms, but also may affect areas of functioning including self-care and usual activities.

**Resource use**

Resource use data for each person were collected over a retrospective period of 6 months before randomisation. At 13 weeks, follow-up data were collected retrospectively for a 3-month period and at 39 weeks for a retrospective period of 6 months. Services and support received by the study participants were recorded on a resource use questionnaire adapted from the Client Service Receipt Inventory (CSRI),54 including inpatient stays, outpatient attendances, day hospital treatment, visits to social clubs, meals at lunch clubs, day care visits, hours spent in contact with community-based professionals such as community teams for older people, community psychologist, community psychiatrist, general practitioners, nurses (either practice, district or community psychiatric), social workers, occupational therapist, paid home help or care workers, physiotherapist. The study also collected data on the use of voluntary organisation services such as volunteer support, befriending and telephone care-line support, and also on unpaid support provided by friends and relatives. Contacts made with voluntary support and support provided by friends and relatives were also measured in physical units, such as hours of care support time. The prescribed daily doses for the medications were calculated from the trial medication log, and prescribing periods were weighted to the changing dose regime.

**Unit costs**

All unit costs were estimated at 2009/2010 prices and were collected from sources in the public domain. Unit costs are summarised in Table 2. Costs per unit of measurement for each type of service (such as per inpatient day, per appointment, per attendance, per visit or per contact with health and community based professionals including voluntary services) were taken from Curtis.55 The National Health Service Schedule of Reference Costs56 was used to estimate the cost of outpatient attendances. The unit cost of medication was obtained from the British National Formulary.57

We collected information on the volume and nature of informal care inputs, mindful of the difficulties of measuring such dimensions and of their interpretation as inputs to the care process. Costs were attached to informal care inputs using a replacement cost – the unit cost of a paid local authority home care worker.55 This approach allowed us to quantify how much it would cost to replace the informal carer with the services from the market. In sensitivity analyses we examined whether the cost-effectiveness results would change under other assumptions.

**Table 2 Unit cost for 2009-2010**

|  |  |  |
| --- | --- | --- |
| **Service** | **Unit cost (£)** | **Source** |
| **Inpatient (bed days)** | 299 | Curtis 201055 |
| Day hospital (attendance) | 50-205 | NHS Reference costs 2009-1056; Curtis 200758; Curtis 2010 |
| Outpatient (appointment) | 21-165 | NHS Reference costs 2009-10 |
| Accident and emergency (attendance) | 37; 97 | Curtis 2010 |
| General practitioner (per surgery consultation) | 28 | Curtis 2010 |
| Geriatrician (min) | 1.83 | Curtis 2010 |
| Nurse (min) 1 | 0.43-0.52 | Curtis 2010 |
| Occupational therapist (min) | 0.65 | Curtis 2010 |
| Community psychiatrist (min) | 1.83 | Curtis 2010 |
| Counsellor (min) | 0.57 | Curtis 2010 |
| Psychologist (min) | 1.20 | Curtis 2010 |
| Chiropodist (contact) | 0.37 | Curtis 2010 |
| Social worker (min) | 0.67 | Curtis 2010 |
| Care manager (min) | 0.82 | Curtis 2010 |
| Home care worker/care attendant (min) | 0.35 | Curtis 2010 |
| Sitting scheme (min) | 0.45 | Curtis 2010 |
| Self-help group (min) | 0.57 | Curtis 2010 |
| Meals on wheels (meal) | 4.8 | <http://www.ic.nhs.uk/webfiles/publications/009_Social_Care/>pss0910expfinal/pss0910updateOct2011/Personal\_Social\_Services\_Expenditure\_Report\_2009\_10.pdf |
| Dentist (min) | 2.90 | NHS Reference costs 2009-10 |
| Optician (min) | 0.48 | Individual calculation 2 |
| Day care (day) | 42-66 | Curtis 2010 |
| Lunch club (meal) | 7 | <http://cash-online.org.uk/content/1/6/3/> ; uprated using the Consumer Price Index (CPI) |
| Social club (session) | 5 | Cost of adult social club at 2004/05 uprated using the pay and prices inflator (Curtis 2010) |

**Notes:**

1. Practice nurse, district nurse health visitor, community psychiatric, cardiac nurse, incontinence nurse
2. There is a recommended fee payable to for ophthalmic medical practitioners who administer sight tests, however Optometrists undertake the majority of tests. The salaries of Optometrists can vary depending on the setting in which they practice (private or hospital or combination of the two). The range of typical salaries in private practice based on salary data collected June 2009 (<http://www.prospects.ac.uk/optometrist_salary.htm>) was £19,500 - £28,000 while in hospital optometrist are usually covered by the Agenda for Change pay scale consisting of nine pay bands. Typical salaries for the pre-registration year start at £18,152 (band 4). Typical starting salaries range from £25,472 - £34,189 (band 6). Specialist optometrists can earn £30,460 - £40,157 (band 7) and principal optometrists £38,851 - £55,945 (band 8a/8b).Typical salaries for consultant optometrists range from £54,454 - £80,810 (band 8c/8d). Working hours are usually nine to five thirty, Monday to Saturday. Hours worked can vary but Optometrist generally work 38 hours per week. The average salary for private practice was used. The cost per hour was estimated based on 41 weeks per annum, 38 hours per week.

**Cost estimation**

Three main categories of costs were analysed: medication costs, aggregated health and social care costs (primary care and hospital outpatient visits, inpatient admissions and community-based health and social care) and cost of time spent care-giving by relatives and friends. Cost were categorised in this way to facilitate the comparison of costs alongside measures of effectiveness from the perspectives for the economic analysis previously defined. The costs of services and support used by patients were derived by combining medication, health and social care resource utilisation data with estimated unit costs. Costs were calculated for the periods 0-13 weeks and for the period 0-39 weeks.

**Statistical analysis**

Cost data were analysed in a similar way to the effectiveness data. Health and social care costs for 0-13 months and 0-39 months (and health, social care and costs of informal care costs for the parallel analysis from the broader perspective for the same time periods) were regressed in turn on treatment allocation, baseline cost, baseline CSDD and centre. To mitigate the effects of skew-ness, non-parametric bootstrapping methods – which avoid the distributional assumptions of parametric testing by use of re-sampling – were used to estimate 95% CIs for mean costs. Where the bias-corrected 95% CIs of between-group change scores excluded zero, they could be judged to be significant at p=0·05.

Estimates of bootstrapped mean cost and effectiveness were used to estimate an incremental cost-effectiveness ratio (ICER) for each analysis. The incremental cost-effectiveness ratio for each replication was calculated as [(costb – costa)/ (effectb – effecta)], which summarises the cost difference between two treatments per incremental difference in the outcome (CSDD and EQ-5D in turn). The EQ-5D was measured directly from patients – as recommended by NICE guidelines (2008) – and weighted by a valuation of changes in quality of life reported from UK population data. The value of health effects was then expressed in terms of quality-adjusted life years (QALYs). The ratio statistic compared the treatments in terms of observed differences in costs and effects, regardless of whether the difference in costs and effects were statistical significant.

Uncertainty around the costs and effectiveness estimates was addressed by plotting cost-effectiveness acceptability curves (CEAC). A CEAC assesses trade-offs between costs and outcomes, showing the likelihood of each of the two medications in turn being seen as cost-effective relative to the other or relative to placebo, given different (implicit monetary) values placed on incremental outcome improvements. In this *net benefit* *approach*, monetary values of incremental effects and incremental costs for each case are combined, and the net benefit derived as:

NB = λ x (effectb - effecta ) – (costb – costa),

Where: a = control, b = drug treatment, NB = net benefit, λ = willingness to pay for unit improvement in CSDD-depression severity score or an additional QALY.

The impact on costs given uncertainty around the value attached to informal care inputs was assessed in one-dimensional sensitivity analysis.

All analyses were done in Stata (version 11) and SPSS 17.

**CHAPTER 3: RESULTS**

**Participant flows**

The CONSORT diagram shows the flow of participants through the trial, Figure 1.

***Figure 1: Participant flows in the HTA-SADD Trial***

Withdrawal from treatment implies that the participant remains in the trial. Withdrawal from the trial implies the participant withdrawal from the trial and treatment. These two categories are mutually exclusive. MMSE = mini-mental state examination. CSDD = Cornell scale for depression in dementia.

**Trial Recruitment**

Over the course of the trial there were 9 recruiting sites, all in the UK. These were Birmingham, Cambridge, Leicester, Liverpool, Manchester, Newcastle, north London, Southampton and South London. Randomisation was stratified by site; all sites successfully recruited. Recruitment began in December 2006 and ended in January 2010. Follow-up interviews were completed by October 2010. In total, 664 individuals were screened as potential participants, of these 326 (49%) were randomised. The overall recruitment rate is shown in Figure 2. The number of participants recruited per site ranged from 7 to 60 (Table 3).

***Figure 2: Cumulative recruitment over the trial period (revised target)***



**Baseline Data**

In total 326 participants were randomised in the trial; 111 to the placebo arm, 107 to the sertraline arm and 108 to the mirtazapine group. All participants completed the CSDD baseline questionnaire. Baseline demographics are summarised for participant and carers. The total number of collected questionnaires completed is featured. Table 3 shows the participant and carer demographics, data collected on clinical characteristics is summarised in Table 3. Groups were evenly matched

The majority of participants were female, and had a mean age 79 years; ranging from 47 to 98 years. 146 (45%) of participants were married and the majority ethnicity was white.

The carers ranged in age from 22 to 95 years, mean age was 61 . Again the majority were female, a higher proportion of the carers were married (63%) compared to the participants. On average 23% of carers were paid workers.

***Table 3: Baseline demographics of participants and carers***

|  |  |  |
| --- | --- | --- |
|  | **Participant** | **Carer** |
|  | Placebo (n=111) | Sertraline (n=107) | Mirtazapine (n=108) | Placebo (n=111) | Sertraline (n=107) | Mirtazapine (n=108) |
| **Age (years)** | 79 (8.8) | 80 (8.4) | 79 (8.4) | 59 (14.8) | 61 (13.9) | 61 (17.1) |
| **Sex (male)** | 40 (36%) | 34 (32%) | 31 (29%) | 46 (30%) | 37 (30%) | 48 (35%) |
| **Ethnicity (white)** | 104(94%) | 98 (92%) | 101 (94%) | 119 (79%) | 109 (89%) | 119 (86%) |
| **Marital status (married)** | 48 (43%) | 51 (48%) | 60 (56%) | 93 (62%) | 82 (67%) | 85 (61%) |
| **Residence (lives in care home)** | 20 (18%) | 13 (12%) | 17 (16%) | - | - | - |
| **Relation to participant (paid carer)** | - | - | - | 40 (26%) | 19 (15%) | 34 (24%) |

Data are mean (sd) or n (%)

Clinical characteristics of participants and carers are shown in Table 4. Completeness of data varies from 74%, MMSE to 100% CSDD, primary outcome measure. Clinical characteristics are balanced over treatment arms. Participant qualities of life have worst outcomes when rated by carers in comparison to the participant rating of equivalent scales.

The mean overall dosages (including participants who withdrew from medication) were 70mg (SD 52) per day for sertraline and 24 mg (16) per day for mirtazapine. For participants who remained on prescribed medication the mean dose was 95 mg (36) per day for sertraline and 30 mg (23) per day for mirtazapine.

***Table 4: Baseline participant and carer clinical characteristics***

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Placebo** | **Sertraline** | **Mirtazapine** |
| **Duration of Depression** |
| Data available  | 111 (100%) | 102 (95%) | 106 (98%) |
| 1 month | 7 (6%) | 3 (3%) | - |
| 1-2 months | 4 (4%) | 6 (6%) | 10 (9%) |
| 2-6 months | 24 (22%) | 18 (17%) | 26 (25%) |
| >6 months | 76 (68%) | 75 (71%) | 70 (66%) |
| **Severity of depression** |
| CSDD 8 -11 | 43 (39%) | 45 (42%) | 54 (50%) |
| CSDD ≥12 | 68 (61%) | 64 (58%) | 54 (50%) |
| Dementia vascularity | 2.1 (1.3) | 2.2 (1.3) | 2.2 (1.3) |
| **Carer-rated scores** |
| **Participant SF-12**  |  |  |  |
| Data available | 103(93%) | 101 (94%) | 96 (89%) |
| Physical component (0-100) | 43.2 (10.6) | 45.2 (11.2) | 44.9 (12.4) |
| Mental Component (0-100) | 50.1 (11.8) | 47.9 (11.1) | 46.1 (12.5) |
| **Participant generic quality of life**  |  |  |  |
| Data available | 109 (99%) | 106 (99%) | 105 (97%) |
| EuroQOL VAS (0-100) | 52.3 (21.1) | 53.8 (19.6) | 51.9 (22.4) |
| **Participant depression** |  |  |  |
| Data available | 111 (100%0 | 107 (100%) | 108 (100%) |
| CSDD (0-38) | 13.6 (5.2) | 12.8 (3.6) | 12.5 (3.7) |
| **Participant activity limitation**  |  |  |  |
| Data available | 111 (100%) | 106 (99%) | 107 (99%) |
| BADL (0-60) | 18.2 (11.1) | 16.6 (11.2) | 18.4 (10.9) |
| **Participant quality of life**  |  |  |  |
| Data available | 91 (82%) | 97 (91%) | 91 (84%) |
| DEMQOL proxy (31 -124) | 88.4 (15.3) | 86.5 (15.6) | 86.9 (13.1) |
| **Carer mental health** |  |  |  |
| Data available | 105 (95%) | 103 (96%) | 98 (91%) |
| GHQ-12 (0-36) | 12.6 (5.1) | 12.5 (4.9) | 13.0 (5.9) |
| **Carer burden** |  |  |  |
| Data available | 87 (78%0) | 93 (87%) | 91 (84%) |
| Zarit (0-88) | 27.2 (16.6) | 27.8 (14.7)  | 26.1 (16.0) |
| **Participant neuropsychiatric symptoms** |  |  |  |
| Data available | 106 (95%) | 104 (97%) | 108 (100%) |
| NPI (0-144) | 30.2 (17.6) | 26.9 (16.8) | 29.9 (20.9) |
| **Participant–rated scores** |
| **Participant cognition** |  |  |  |
| Data available | 82 (74%) | 79. (74%) | 90 (83%) |
| Standardised MMSE (0 -33) | 18.2 (7.4) | 18.5 (6.7) | 17.6 (6.0) |
| **Participant generic quality of life** |  |  |  |
| Data available | 92 (83%) | 86 (80%) | 91 (84%) |
| EuroQOL VAS (0-100) | 60.3 (24.1) | 66.6 (17.8) | 66.9 (18.5) |
| **Participant generic quality of life** |  |  |  |
| Data available | 87 (78%) | 82 (77%) | 91 (84%) |
| DEMQOL (28-122) | 83.7 (17.2) | 82.5 (14.3) | 85.1 (12.8) |

Data are n(%) or mean(SD). SF = short form health survey. VAS=visual analogue scale. CSDD= Cornell scale for depression in dementia. BADL=Bristol Activities of Daily Living. GHQ=general health questionnaire. NPI =Neuropsychiatric inventory. MMSE=mini mental state examination.

**Data collection**

The mean (SD) time interval between randomisation and completion of questionnaires was 18.2 (14.19) weeks at the 13-week assessment time point and 42.15 (10.7) weeks at the 39 week assessment. The distribution of initiation of treatment following randomisation is shown in Figure 3. Out of the 326 participants randomised, 321 received allocated treatment.

***Figure 3: Distribution of initiation of treatment from randomisation***

****

**Numbers analysed**

111 participants were randomised to placebo, 107 to sertraline, and 108 to mirtazapine. The number of participants included in each analysis is indicated in the tables.

**Outcomes and estimation**

**Primary outcome: CSDD**

In total, 258 participants completed the research worker rated CSDD at 13 weeks post randomisation, with 226 participants going on to completed the measure at 39 weeks. As measured by the CSDD severity of depression was shown to decrease in all three intervention groups, compared with baseline. The results of which can be seen in Figure 3. The absolute change from baseline at 13 weeks was greatest for placebo -5.6 (SD 4.7), compared to -3.9 (5.1) for sertraline and -5.0 (4.9) for mirtazapine. This was difference was maintained through to 39 weeks, change scores of -4.8 (5.5) for placebo, -4.0 (5.2) for sertraline and -5.0 (6.1) for mirtazapine.

***Figure 4: CSDD scores by treatment group, unadjusted means with 95% CI (a lower CSDD score means less depressive symptoms).***



The results from the linear mixed modelling, Table 4, after adjusting for baseline depression and the stratification factor centre highlighted that there was no evidence of a difference between sertraline and placebo or mirtazapine and placebo, on the CSDD score at 13 or 39 weeks. This analysis provides robust evidence of an absence of clinical effectiveness of the antidepressants tested here compared with placebo.

On exploratory analysis of the primary outcome measure, we classified the participants as suffering from depression based on the CSDD, a score of 8 or higher is threshold for depression, Table 5. As part of our eligibility criteria all participants at baseline had depression. This criteria was examined at 13 and 39 weeks. By 13 weeks the same proportion of participants in all treatment arms had moved to the no depression classification (49%), the main deviation from this trend was seen at 39 weeks where Mirtazapine showed the largest percentage of non-depressive arm (55%). On evaluation with from a generalised linear mixed model (using the a logit link for the dichotomous data) adjusting for baseline depression and the stratification factor centre, there was no evidence for a difference in the proportion of participants classified with depression by the CSDD at 13 or 39 weeks, between treatment arms, table 6.

***Table 5: Primary outcomes of research worker rated CSDD score***

|  |  |
| --- | --- |
|  | **CSDD Score**  |
| **Placebo**  | **Sertraline** | **Mirtazapine** |
| **Baseline mean (sd)** | 13.6 (5.2); n=111 | 12.8 (3.6); n =107 | 12.5 (3.7):n=108 |
| **Week 13 mean (sd)** | 7.8 (4.1): n= 95 | 8.6 (4.9): n=78 | 7.9 (5.0): n= 85 |
| **Week 39 mean (sd)** | 8.5 (5.5): n=82 | 8.6 (5.5): n=68 | 7.7 (6.2): n= 76 |
|  |
| **Mean difference from placebo(SE)** **(95% CI)** **P-value; n**  |
| **13 weeks** | - | 1.17 (0.72)(-0.23 to 2.78)0.10; n=173 | 0.01 (0.70)(-1.37 to 1.38)0.99; n=180 |
| **39 weeks**  | - | 0.38 (0.76)(-1.12 to 1.87)0.63; n=150 | -0.67 (0.74)(-2.12 to 0.79)0.37; n=158) |
|  |
| **Mean difference From mirtazapine** **(95% CI)****P-value; n** |
| **13 weeks** | - | 1.16 (0.72)(-0.25 to 2.57)0.11; n=163 | - |
| **39 weeks**  | - | 1.04 (0.76)(-0.48 to 2.56)0.18; n=144 | - |

***Table 6: proportion of participants with depression***

|  |  |  |  |
| --- | --- | --- | --- |
| **Visit**  | **Baseline** | **Week 13** | **Week 39** |
| **Treatment**  | **Depression** | **Depression** | **Depression** |
| **No** | **Yes** | **No** | **Yes** | **No** | **Yes** |
| Placebo |  | 111 | 47 (49%) | 48 | 40 (49%) | 42 |
| Sertraline |  | 107 | 38 (49%) | 40 | 33 (47%) | 37 |
| Mirtazapine |  | 108 | 42 (49%) | 43 | 42 (55%) | 34 |
| Total |  | 326 | 127 | 131 | 115 | 111 |

Number (%) of cases of depression

***Table 7: Generalised linear mixed modelling of depression classification***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Odds Ratio** | **Std. Err.** | **P-value** | **(95% Conf. Interval)** |
| Week 13 sertraline vs. placebo | 1.050 | 0.349 | 0.883 | 0.547  | 2.016 |
| Week 13 mirtazapine vs. placebo | 1.008 | 0.327 | 0.979 | 0.534 | 1.906 |
| Week 13 sertraline vs. mirtazapine | 1.042 | 0.351 | 0.904 | 0.538 | 2.018 |
|  |  |  |  |  |  |
| Week 39 sertraline vs. placebo | 1.077 | 0.408 | 0.845 | 0.512 | 2.263 |
| Week 39 mirtazapine vs. placebo | 0.692 | 0.256  | 0.319 | 0.335 | 1.428 |
| Week 39 sertraline vs. mirtazapine | 1.557 | 0.596 | 0.247 | 0.736 | 3.296 |

Adjusted logistic Model for depression status at 13 and 39 weeks, full adjusted model.

**Secondary outcomes**

Table 8 shows the effectiveness of the medications compared with placebo and between each other on secondary outcomes in participants and carers. Again, few differences can be attributed to the antidepressants. However, there were fewer neuropsychiatric symptoms and higher carer-rated participant scores for health related quality of life (DEMQOL-proxy) in participants given mirtazapine compared with sertraline, but these differences did not persist to 39 weeks (table 4).

Our findings did not differ in subgroup analyses examining outcomes by baseline depression severity (CSDD score 8–11 vs ≥12). All but eight participants (one in the placebo group, three in the sertraline group, and four in the mirtazapine group) met criteria for categorical diagnosis of depression in Alzheimer’s disease as per Olin criteria.49 Sensitivity analyses with the Olin criteria as a moderator were not appropriate because of the low frequency of participants who did not meet Olin criteria. However, this gives reassurance of the clinical significance of the depression in dementia investigated here.

Carers whose relatives were receiving placebo had higher quality of life scores at 13 weeks (SF-12 mental component score) and higher mental health scores (GHQ-12) than did those on sertraline (table 8). Finally, carers of participants in the mirtazapine group had higher quality of life scores (SF-12 mental component score) at 13 weeks than did the carers of participants in the sertraline group. However, these differences did not persist at 39 weeks.

***Table 8: Comparisons of secondary participant carer outcome (including depression severity)***

|  |  |  |
| --- | --- | --- |
|  | **Week 13** | **Week 39** |
| **Sertraline v****Placebo** | **Mirtazapine v****Placebo** | **Sertraline v****mirtazapine** | **Sertraline v****Placebo** | **Mirtazapine v****Placebo** | **Sertraline v****mirtazapine** |
| **Cognition****MMSE** | Coeff (SE)95% CI (p value) | -0.22 (0.65)-1.50 to 1.05(0.73) | -0.27 (0.61)-1.48 to 0.94(0.66) | 0.05 (0.64)-1.21 to 1.31(0.94) | -0.55 (0.68)-1.89 to 0.79(0.42) | -1.71 (0.67)-2.48 to 0.14(0.08) | 0.62 (0.69)-0.73 to 1.97(0.37) |
| **Activity limitation****BADL** | Coeff (SE)95% CI (p value) | 1.40 (1.26)-1.07 to 3.88(0.27) | -0.04 (1.23)-2.44 to 2.36)(0.97) | 1.44 (1.30)-1.10 to 3.99(0.27) | 1.63 (1.35)-1.01 to 4.27(0.26) | 1.19 (1.30)-1.37 to 3.75(0.36) | 0.44 (1.38)-2.26 to 3.14(0.75) |
| **Behaviour****Problems****NPI** | Coeff (SE)95% CI (p value) | 2.72 (2.41)-2.01 to 7.45(0.26) | -3.56 (2.30)-8.07 to 0.96(0.12) | 6.28 (2.42)1.53 to 11.03**(0.010)** | 2.02 (2.53)-2.94 to 6.97(0.43) | -1.51 (2.42)-6.25 to 3.24(0.53) | 3.53 (2.53)-1.44 to 8.49(0.164) |
| **Depression severity** |  |  |  |  |  |  |
|  **low CSDD score****8-11** | Coeff (SE)95% CI (p value | 1.12 (1.01)-0.85 to 3.10(0.26) | -0.30 (0.98)-2.21 to 1.61(0.76) | 1.43 (0.99)-0.51 to 3.36(0.15) | 0.33 (1.04)-1.72 to 2.37(0.76) | -0.99 (1.02)-2.98 to 1.00(0.33) | 1.31 (1.04)-0.72 to 3.34(0.20) |
|  **high CSDD score****12+** | Coeff (SE)95% CI (p value | 1.18 (0.91)-0.60 to 2.96(0.34) | 0.27 (0.89)-1.47 to 2.01(0.76) | 0.91 (0.91)-0.95 to 2.77(0.34) | 0.38 (0.94)-1.47 to 2.230.69 | -0.41 (0.91)-2..20 to 1.370.65 | 0.0.80 (0.97)-1.10 to 2.690.41 |
| **Life quality** **DEMQOL** | Coeff (SE)95% CI (p value) | 0.30 (1.89)-3.40 to 4.01(0.87) | -0.06 (1.76)-3.52 to 3.39(0.97) | 0.37 (1.89)-3.52 to 3.39(0.85) | -1.76 (2.04)-5.75 to 2.23(0.39) | -0.03 (1.92)-3.80 to 3.75(0.99) | -1.74 (2.07)-5.79 to 2.32(0.40) |
| **Life quality DEMQOL-Proxy** | Coeff (SE)95% CI (p value) | -1.98 (2.14)-6.16 to 2.21(0.36) | 3.13 (2.15)-1.09 to 7.35(0.15) | -5.11 (2.22)-9.45 to -0.76**(0.021)** | 2.69 (2.28)-1.77 to 7.15(0.24) | 3.69 (2.28)-0.77 to 8.16(0.11) | -1.00 (2.35)-5.61 to 3.60(0.67) |
| **Life quality****Self-rated** **EQ5D** | Coeff (SE)95% CI (p value) | -3.44 (3.78)-10.86 to 3.98 (0.36) | 2.00 (3.67)-5.18 to 9.19(0.59) | -5.44 (3.72)-5.18 to 9.19(0.14) | -4.34 (4.19)-12.56 to 3.88(0.30) | -1.18 (4.12)-9.25 to 6.89(0.78) | -3.16 (4.21)-9.25 to 6.89(0.45) |
| **Life quality****Carer-rated****EQ5D** | Coeff (SE)95% CI (p value) | 0.61 (3.05)-5.38 to 6.59(0.84) | 3.62 (3.03)-2.31 to 9.55(0.23) | -3.02 (3.17)-9.23 to 3.20(0.34) | -0.27 (3.32)-6.77 to 6.24(0.94) | -1.11 (3.23)-7.44 to 5.21(0.73) | 0.85 (3.42)-5.86 to 7.56(0.80) |
| **Carer burden Zarit** | Coeff (SE)95% CI (p value) | -0.50 (1.93)-4.28 to 3.27(0.80) | -1.14 (1.83)-4.93 to 0.65(0.56) | 0.64 (1.98)-3.23 to 4.51(0.75) | -0.09 (2.07)-4.15 to 3.98(0.97) | -2.80 (2.14)-6.99 to 1.38(0.19) | 2.71 (2.13)-1.45 to 6.88(0.20) |
| **Carer mental health GHQ** | Coeff (SE)95% CI (p value) | 1.47 (0.72)0.06 to 2.89**(0.042)** | -0.57 (1.23)-0.84 to 1.98(0.43) | 0.90 (0.75)-0.56 to 2.37(0.23) | 0.43 (0.77)-1.09 to 1.95(0.58) | -0.61 (0.77)-2.12 to 0.90(0.43) | 1.04 (0.80)-0.53 to 2.61(0.20) |
| **Life quality****SF-12 PCS****physical** | Coeff (SE)95% CI (p value) | 1.28 (1.40)-1.48 to 4.03(0.36) | -0.53 (1.39)-2.20 to 3.26(0.70) | 0.75 (1.45)-2.10 to 3.59(0.61) | -1.68 (1.48)-4.58 to 1.22(0.26) | 0.02 (1.46)-2.84 to 2.88(0.99) | -1.70 (1.53)-2.84 to 2.88(0.27) |
| **Life quality****SF-12 MCS****Mental** | Coeff (SE)95% CI (p value) | -2.99 (1.47)-5.87 to -0.11**(0.042)** | 0.52 (1.45)-2.31 to 3.36(0.72) | -3.52 (1.52)-6.50 to -0.54**(0.021)** | 0.09 (1.54)-2.94 to 3.11(0.96) | -0.31 (1.51)-3.28 to 2.66(0.84) | 0.40 (1.60)-2.74 to 3.54(0.80) |

**NPI**

The distributional assumptions of the regression model were improved by specifying a negative binomial distribution for the NPI data. The data was examined cross sectionally, thus missing data was accounted for by inverse probability weighting. The subscales of the NPI can be combined to yield four factors: Factor 1 Agitation, Disinhibition and Irritability; Factor 2 Delusions, Depression and Anxiety; Factor 3: Hallucinations, Aberrant motor behaviour and Sleep; Factor 4 Elation, Apathy: Appetite. The summaries for the factors came be seen in table 9. Under the new regression model, there is evidence for a beneficial effect of mirtazapine in comparison to sertraline. The difference in odds between sertraline and placebo, although non-significant, trends towards a better outcome in placebo. These differences are seen at 13 weeks, table 10.

The significant odds seen for the total score (OR 1.39; 95% CI 1.08-1.78, P=0.009), is supported by factors 2 and 3. These effects are not continued into week 39.

***Table 9: mean (SD) of the NPI factors***

|  |  |  |  |
| --- | --- | --- | --- |
| **Baseline**  | **Placebo** | **Sertraline** | **Mirtazapine** |
| **Data available****Mean (sd)** |
| **Baseline**  |
| Factor1 | 1106.89 (6.44) | 1075.87 (5.53) | 1086.5 (6.67) |
| Factor2 | 1119.18 (6.65) | 1058.76 (6.33) | 1089.42 (7.55) |
| Factor3  | 1116.41 (6.73) | 1065.71 (5.57) | 1086.36 (7.21) |
| Factor4 | 1077.43 (6.25) | 1056.62 (5.18) | 1087.58 (6.44) |
| **Week 13**  |
| Factor1 | 974.30 (4.65) | 794.58 (5.32) | 884.28 (5.68) |
| Factor2 | 965.21 (5.59) | 795.85 (6.62) | 884.17 (5.54) |
| Factor3  | 974.41 (5.14) | 795.43 (6.02) | 884.02 (5.74) |
| Factor4 | 93 5.53 (5.56) | 755.25 (5.65) | 884.42 (4.73) |
| **Week 39**  |
| Factor1 | 845.08 (5.58) | 704.91 (6.03) | 784.36 (5.88) |
| Factor2 | 845.37 (5.48) | 695.61 (6.44) | 785.32 (7.08) |
| Factor3  | 833.39 (4.83) | 704.46 (5.35) | 784.34 (6.22) |
| Factor4 | 815.59 (5.57) | 685.68 (5.38) | 785.19 (6.45) |

***Table 10: Odds ratio, the NPI and derived factor scores. Fully adjusted modelling***

|  |  |  |
| --- | --- | --- |
|  | **Week 13** | **Week 39** |
| **Sertraline v****Placebo** | **Mirtazapine v****Placebo** | **Sertraline v****Mirtazapine** | **Sertraline v****Placebo** | **Mirtazapine v****Placebo** | **Sertraline v****mirtazapine** |
| **Total Score** | Odds Ratio (SE)95% CI (p value) | 1.098 (0.12)0.884 to 1.3630.397 | 0.790 (0.10)0.618 to 1.0090.059 | 1.390 (0.18)1.084 to 1.782**0.009** | 1.150 (0.15)0.884 to 1.4950.298 | 0.933 (0.14)0.693 to 1.2560.647 | 1.232 (0.18)0.926 to 1.6400.151 |
| **Factor 1** | Odds Ratio (SE)95% CI (p value) | 1.104 (0.19)0.782 to 1.5580.573 | 1.013 (0.21)0.678 to 1.5160.948 | 1.090 (0.24)0.706 to 1.6810.698 | 1.101 (0.233)0.728 to 1.6660.649 | 0.913 (0.19)0.608 to 1.3720.663 | 1.206 (0.28)0.760 to 1.9110.427 |
| **Factor 2** | Odds Ratio (SE)95% CI (p value) | 1.203 (0.22)0.840 to 1.7230.313 | 0.738 (0.13)0.516 to 1.0540.095 | 1.631 (0.30)1.141 to 2.331**0.007** | 0.996 (0.18)0.697 to 1.4250.984 | 0.886 (0.17)0.609 to 1.2870.524 | 1.125 (0.21)0.775 to 1.6340.536 |
| **Factor 3** | Odds Ratio (SE)95% CI (p value) | 1.395 (0.26)0.964 to 2.0180.078 | 0.716 (0.17)0.451 to 1.1380.158 | 1.946 (0.45)1.239 to 3.056**0.004** | 1.663 (0.42)1.020 to 2.713**0.042** | 1.398 (0.35)0.856 to 2.2830.181 | 1.190 (0.26)0.779 to 1.8190.422 |
| **Factor 4**  | Odds Ratio (SE)95% CI (p value) | 1.064 (0.18)0.762 to 1.4860.715 | 0.853 (0.13)0.633 to 1.1480.294 | 1.248 (0.22)0.887 to 1.7550.204 | 1.141 (0.21)0.786 to 1.6560.488 | 0.842 (0.17)0.570 to 1.2440.387 | 1.355 (0.27)0.912 to 2.015 0.133 |

**Safety data**

In total, 119 participants reported 240 adverse reactions. Table 11 shows adverse reactions by week 39. 29 of 111 participants (26%) in the placebo group had adverse reactions, compared with 46 of 107 (43%) in the sertraline group (p=0·010) and 44 of 108 (41%) in the mirtazapine group (p=0·031; overall p value for placebo vs either drug 0·017). Gastrointestinal reactions were most common with sertraline (usually nausea) and psychological reactions were most common with mirtazapine (usually drowsiness and sedation). At 13 weeks, there were 15 serious adverse events in the placebo group of which three (20%) were rated severe, compared with 12 in the sertraline group (eight severe [67%]) and 14 (10 severe [71%]) in the mirtazapine group. Overall, the number of serious adverse events reported did not differ between groups but more of these events were severe in those on antidepressants compared with placebo (p=0·003). Mortality did not differ between groups (five deaths in each group by 39 weeks).

***Table 11: Adverse reactions definite, probable, and possibly related top study intervention by week 39.***

|  |  |  |
| --- | --- | --- |
| Classification | Treatment Group | Total Events |
| placebo (events) | sertraline (events) | mirtazapine (events) |
| Psychological | 10 (22) | 9 (18) | 24 (44) | 53 (84) |
| Neurological | 8 (9) | 16 (25) | 18 (21) | 42 (55) |
| Gastrointestinal | 7 (7) | 20 (24) | 11 (13) | 38 (44) |
| Other | 2 (2) | 5 (5) | 3 (3) | 10 (10) |
| Genitourinary | 4 (4) | 3 (3) | 2 (3) | 9 (10) |
| Musculoskeletal | 2 (3) | 3 (3) | 3 (3) | 8 (9) |
| Dermatological  | 3 (4) | 3 (3) | 2 (2) | 8 (9) |
| Respiratory | 2 (2) | 1 (1) | 2 (2) | 5 (5) |
| Cardiovascular | 1 (1) | 0 (0) | 2 (4) | 3 (5) |
| Infection | 1 (1) | 1 (1) | 1 (1) | 3 (3) |
| ENT | 2 (2) | 1 (1) | 0 (0) | 3 (3) |
| Haematological | 1 (1)  | 1 (1) | 0 (0) | 2 (2) |
| Endocrine  | 0 (0) | 1 (1) | 0 (0) | 1 (1) |
| Total\*\*  | 29 (58) | 46 (86) | 44 (96) | 119 (240) |

Data are number of participants (number of events)

**Health Economic Results**

**Baseline comparisons**

At baseline, full service use data were available for 326 participants (111 placebo, 107 sertraline, 108 mirtazapine). At 13 weeks economic data were available for 97 participants in the placebo group, 78 in the sertraline group and 88 in the mirtazapine group. By 39 weeks there were 84 participants in the placebo group, 69 in the sertraline group and 77 in the mirtazapine group.

**Service use and support**

Contacts made by patients with services and support over weeks 0-13 and 0-39 are shown in Table 12. There were few differences between the three patient groups in either time period, except when mirtazapine and sertraline were compared with placebo and mirtazapine was compared with sertraline. There were no statistically significant differences between the groups in the number of contacts with any services.

**Table 12 Service use**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Placebo**  | **Sertraline** | **Mirtazapine** |
| **Week 0-13** | **n=97** | **n=78** | **n=88** |
|  | **No. using** | **Mean a(SD)** | **No. using** | **Mean a(SD)** | **No. using** | **Mean a(SD)** |
| **Hospital-based care** |  |  |  |  |  |  |
|  Inpatient (bed day) **b** | 8 | 1.65 (7.98) | 5 | 1.58 (6.82) | 5 | 0.49 (2.19) |
|  Outpatient (attendance)  | 33 | 0.53 (1.08) | 25 | 0.60 (1.10) | 26 | 0.53 (1.10) |
|  Accident and emergency (Attendance) | 8 | 0.12(0.48) | 5 | 0.08 (0.27) | 4 | 0.57 (0.28) |
|  Day hospital (contact) | 3 | 0.23 (1.44) | 6 | 0.83 (4.11) | 4 | 0.32 (1.66) |
| **Community-based care** |  |  |  |  |  |  |
|  GP (contact) | 57 | 1.36 (2.36) | 44 | 1.09 (1.44) | 49 | 1.22 (2.84) |
|  Geriatrician (contact) | 3 | 0.03 (0.17) | 0 | 0 | 88 | 0.03 (0.18) |
|  Nurse\* (contact) | 41 | 0.87 (1.49) | 29 | 2.50 (10.83) | 43 | 1.56 (3.71) |
|  Occupational therapist (contact) | 11 | 0.21 (0.66) | 7 | 0.35 (1.70) | 5 | 0.08 (0.38) |
|  Community psychiatrist (contact) | 21 | 0.26 (0.54) | 14 | 0.24 (0.63) | 19 | 0.27 (0.58) |
|  Psychologist (contact) | 2 | 0.82 (0.64) | 3 | 0.06 (0.37) | 2 | 0.09 (0.62) |
|  Counsellor (contact) | 1 | 0.01 (0.10) | 3 | 0.36 (2.94) | 2 | 0.17 (1.32) |
|  Care manager (contact) | 7 | 0.10 (0.42) | 1 | 0.01 (0.11) | 4 | 0.05 (0.21) |
|  Social worker (contact) | 15 | 0.21 (0.69) | 10 | 0.19 (0.58) | 12 | 0.28 (0.87) |
|  Home care worker/care attendant (contact) | 19 | 18.57 (60.57) | 17 | 21.92 (72.77) | 22 | 28.33 (72.19) |
|  Chiropodist (contact) | 33 | 0.43 (0.710 | 16 | 0.26 (0.57) | 23 | 0.40 (0.88) |
|  Sitting scheme (contact) | 5 | 1.21 (6.71) | 5 | 0.68 (4.29) | 3 | 0.59 (3.75) |
|  Self-help group (contact) | 0 | 0 | 0 | 0 | 1 | 0.03 (0.32) |
|  Meals on wheels (contact) | 3 | 0.30 (1.77) | 3 | 5.82 (33.95) | 4 | 2.32 (12.74) |
|  Dentist (contact) | 10 | 0.13 (0.49) | 10 | 0.15 (0.43) | 15 | 0.23 (0.58) |
|  Optician (contact) | 10 | 0.12 (0.39) | 13 | 0.19 (0.46) | 12 | 0.15 (0.39) |
| **Day services** |  |  |  |  |  |  |
|  Day services (day) | 15 | 4.15 (11.95) | 17 | 6.50 (15.64) | 16 | 5.47 (13.33) |
|  Lunch club (visit) | 3 | 1.88 (15.92) | 0 | 0 | 3 | 1.18 (8.51) |
|  Social club (visit) | 2 | 0.27 (1.86) | 4 | 0.67 (2.89) | 2 | 0.44 (3.08) |
| **Informal care** |  |  |  |  |  |  |
|  Care giving (hours/week) | 45 | 10.05 (17.65) | 37 | 11.63 (21.59) | 42 | 9.84 (23.85) |
|  | **Placebo** | **Sertraline**  | **Mirtazapine** |
| **Week 0-39** | **n=84** | **n=69** | **n=78** |
|  Inpatient (bed day) **b** | 9 | 3.05 (10.48) | 11 | 2.55 (9.26) | 14 | 4.54 (15.08) |
|  Outpatient (attendance)  | 44 | 0.83 (1.15) | 33 | 0.90 (1.41) | 29 | 0.69 (1.15) |
|  Accident and emergency (attendance) | 13 | 0.17 (0.41) | 8 | 0.25 (0.86) | 7 | 0.10 (0.35) |
|  Day hospital (contact) | 1 | 0.01 (0.11) | 8 | 2.61 (9.42) | 3 | 0.56 (3.30) |
| **Community based care** |  |  |  |  |  |  |
|  GP (contact) | 57 | 1.51 (1.83) | 40 | 1.52 (2.15) | 55 | 1.88 (2.40) |
|  Geriatrician (contact) | 4 | 0.05 (0.21) | 0 | 0 | 2 | 0.03 (0.16) |
|  Nurse\* (contact) | 37 | 1.24 (2.34) | 33 | 5.84 (29.57) | 34 | 1.46 (3.53) |
|  Occupational therapist (contact) | 9 | 0.17 (0.53) | 8 | 0.45 (2.23) | 5 | 0.10 (0.44) |
|  Community psychiatrist (contact) | 22 | 0.33 (0.67) | 15 | 0.26 (0.53) | 29 | 0.60 (1.48) |
|  Psychologist (contact) | 5 | 0.21 (1.34) | 2 | 0.03 (0.17) | 1 | 0.01 (0.11) |
|  Counsellor (contact) |  |  |  |  |  |  |
|  Care manager (contact) | 6 | 0.52 (2.87) | 3 | 0.04 (0.21) | 5 | 0.10 (0.44) |
|  Social worker (contact) | 12 | 0.58 (2.98) | 15 | 0.42 (0.98) | 17 | 0.44 (1.47) |
|  Home care worker/care attendant (contact) | 16 | 33.56 (107.73) | 19 | 38.07 (95.60) | 17 | 38.95 (110.10) |
|  Chiropodist (contact) | 35 | 0.88 (1.37) | 20 | 0.53 (1.52) | 32 | 1.11 (1.89) |
|  Sitting scheme (contact) | 0 | 0 | 5 | 1.23 (5.49) | 4 | 0.76 (3.69) |
|  Meals on wheels (contact) | 2 | 0.63 (5.67) | 2 | 3.77 (21.70) | 2 | 3.14 (19.49) |
|  Dentist (contact) | 18 | 0.33 (0.96) | 18 | 0.47 (1.25) | 19 | 0.34 (0.81) |
|  Dietician (contact) | 0 | 0 | 0 | 0 | 1 | 0.01 (0.11) |
| **Day services** |  |  |  |  |  |  |
|  Day services (day) | 16 | 5.57 (14.31) | 18 | 7.26 (15.13) | 16 | 5.17 (12.63) |
|  Lunch club (visit) | 1 | 0.31 (2.84) | 1 | 0.38 (3.15) | 3 | 0.83 (4.84) |
|  Social club (visit) | 2 | 0.62 (4.47) | 3 | 0.57 (2.69) | 1 | 0.33 (2.94) |
| **Informal care** |  |  |  |  |  |  |
|  Care giving (hours per week) | 40 | 12.27 (21.24) | 34 | 12.32 (24.07) | 33 | 6.74 (11.82) |

**a**across full sample

b psychiatric and non-psychiatric inpatient bed days

**\***practice nurse, district nurse health visitor, community psychiatric, cardiac nurse, incontinence nurse

**Costs**

Daily medication costs for sertraline 50mg of £0.05 and mirtazapine 15mg of £0.23 were applied. Mean cost of medication per person was estimated to be £7 (CI 6 to 9) and £37 (CI 32 to 41).

Mean total costs over 0-13-weeks and 0-39 weeks are detailed in Table 13. Pairwise comparisons were made between the two antidepressants and placebo using regression analysis and bootstrapping. There were no statistically significant differences between the groups in either of the time periods, either when health and social care service costs only were included, or when health and social care services and informal care costs are summed.

After adjustment for baseline costs, CSDD score at baseline and site, there were no statistically significant differences in health and social care costs – or in health, social care and informal care costs – in any pairwise comparison in either time period.

In terms of observed mean *differences*, aggregated health and social care service costs per patient over 0-13 weeks were £3 between sertraline and placebo, £307 between placebo and mirtazapine and £310 between sertraline and mirtazapine. In each case, the first named treatment was the more costly. In the 6 months leading up to 39 weeks, mean difference in health and social care costs was £693 between sertraline and placebo, £404 between mirtazapine and placebo, and £289 between sertraline and mirtazapine. Again, in each case the first-named treatment was more costly.

Informal care costs exceeded health and social care costs by a factor of 1.2 to 1.7. Including informal care costs results in a change in the ranking of total costs, with mirtazapine being the least expensive of all treatments in both periods.

**Table 13 Health, social care and informal care costs and outcome**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Placebo** |  | **Sertraline** |  | **Mirtazapine** | **Bootstrapped mean difference (95% CI)** |
|  | **N** | **Mean (sd), £** | **n** | **Mean (sd), £** | **n** | **Mean (sd), £** | **Sertraline - Placebo** | **Mirtazapine - Placebo** | **Mirtazapine - Sertraline** |
| (a) Medication costs |  |  |  |  |  |  |  |  |  |
|  0-13 weeks | 97 | 0 | 78 | 7 (5) | 88 | 37 (22) | 7 (6 to 8) | 37 (32 to 41) | 30 (25 to 34) |
|  0-39 weeks | 84 | 0 | 69 | 7 (5) | 78 | 37 (22) | 7 (6 to 8) | 37 (32 to 41) | 30 (25 to 34) |
| (b) Health and social care costs  |  |  |  |  |  |  |  |  |  |
|  0-13 weeks | 97 | 1438 (3339) | 78 | 1434 (2326) | 88 | 1094 (1871) | -4 (-900 to 798) | -344 (-1207 to 322) | -340 (-1049 to 283) |
|  0-39 weeks | 84 | 2146 (4402) | 69 | 2832 (4111) | 78 | 2513 (4290) | 686 (-630 to 1973) | 367 (-977 to 1596) | -319 (-1643 to 1023) |
| (c) Informal care cost  |  |  |  |  |  |  |  |  |  |
|  0-13 weeks | 97 | 2744 (4819) | 78 | 3175 (5897) | 88 | 2687 (6511) | 431 (-1000 to 2242) | -57 (-1686 to 1537) | -488 (-2380 to 1470) |
|  0-39 weeks | 84 | 3351 (5799) | 69 | 3363 (6573) | 78 | 1841 (3228) | 12 (-1940 to 2256) | -1510 (-3088 to -136) | -1522 (-3398 to -72) |
| Total costs *excluding* informal care inputs (a+b) |
|  0-13 weeks | 97 | 1438 (3339) | 78 | 1441 (2327) | 88 | 1131 (1869) | 3 (-893 to 806) | -307 (-1172 to 358) | -310 (-910 to 299) |
|  0-39 weeks | 84 | 2146 (4402) | 69 | 2839 (4112) | 78 | 2550 (4289) | 693 (-622 to 1980) | 404 (-972 to 1626) | -289 (-1545 to 1151) |
| Total costs *including* informal care inputs (a+b+c) |
|  0-13 weeks | 97 | 4182 (5821) | 78 | 4616 (6488) | 88 | 3818 (7060) | 434 (-1340 to 2356) | -365 (-2212 to 1560) | -798 (-2754 to 1498) |
|  0-39 weeks | 84 | 5497 (7922) | 69 | 6202 (8241) | 78 | 4391 (5285) | 705 (-1855 to 3234) | -1106 (-3137 to 970) | -1811 (-4048 to 543) |
| Depression score (CSDD)  |  |  |  |  |  |  |  |  |  |
|  13 weeks | 95 | 7.8 (4.1) | 78 | 8.6 (4.9) | 85 | 7.9 (5.0) | 0.84 (-0.60 to 2.14) | 0.16 (-1.53 to 1.11)  | -0.7 (-0.57 to 2.52) |
|  39 weeks | 82 | 8.5 (5.5) | 68 | 8.6 (5.5) | 76 | 7.7 (6.2) | 0.05 (-1.83 to 1.67) | -0.80 (-2.55 to 1.21) | -0.9 (-1.10 to 2.73) |
| QALY 39 weeks (EQ-5D) | 57 | 0.55 (0.17) | 53 | 0.57 (0.14) | 52 | 0.60 (0.13) | 0.03 (-0.09 to 0.03) | 0.05 (-0.10 to 0.01) | 0.02 (-.03 to 0.07) |

**Table 14 Differences in incremental cost, effect, and cost-effectiveness**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Sertraline – placebo** | **Mirtazapine – placebo** | **Mirtazapine - Sertraline** |
|  | **0-13 weeks** | **0-39 weeks** | **0-13 weeks** | **0-39 weeks** | **0-13 weeks** | **0-39 weeks** |
| **Incremental cost (£, 2009/2010)** |  |  |  |  |  |  |
| Health and social care; mean [95% CI] | 3 (-893 to 806) | 693 (-622 to 1980) | -307 (-1172 to 358) | 404 (-972 to 1626) | -310 (-910 to 299) | -289 (-1545 to 1151) |
| Health and social care and Informal care; mean [95% CI] | 434 (-1340 to 2356) | 705 (-1855 to 3234) | -365 (-2212 to 970) | -1106 (-3137 to 970) | -798 (-2754 to 1498) | -1811 (-4048 to 543) |
| **Incremental effect:** |  |  |  |  |  |  |
| CSDD score; mean [95% CI]\* | 0.84 (-0.60 to 2.14) | 0.05 (-1.83 to 1.67) | 0.16 (-1.53 to 1.11) | -0.80 (-2.55 to 1.21) | -0.7 (-0.57 to 2.52) | -0.9 (-1.10 to 2.73) |
| QALY (EQ-5D); mean [95% CI]\*\* | - | 0.03 (-0.09 to 0.03) | - | 0.05 (-0.10 to 0.01) | - | 0.02 (-.03 to 0.07) |
| **Incremental cost-effectiveness (£) - Health and social care and:** |  |  |  |  |  |  |
| 1. CSDD score
 | 4 | 13860 | 1919 | -505 | 443 | 321 |
|  | (Dominated) | (Dominated) | (Lower costs; worse outcome) | (Higher costs; better outcome) | (Mirtazapine dominant) | (Mirtazapine dominant) |
| (b) QALY (EQ-5D) | - | 23100 | - | 8080 | - | -14450 |
|  | - | (Higher costs; better outcome) | - | (Higher costs; better outcome) | - | (Mirtazapine dominant) |
| **Incremental cost-effectiveness (£) - Health and social care and informal care costs and :** |  |  |  |  |  |  |
| 1. CSDD score
 | 517 | 14100 | 2281 | 1382 | 1140 | 2012 |
|  | (Dominated) | (Dominated) | (Lower costs; worse outcome) | (Mirtazapine dominant) | (Mirtazapine dominant) | (Mirtazapine dominant) |
| (b) QALY (EQ-5D) \*\* | - | 23500 | - | -22120 | - | -90550 |
|  | - | (Higher costs; better outcome) | - | (Mirtazapine dominant) | - | (Mirtazapine dominant) |

Dominated = active treatment has higher costs and worse outcome; Dominant = active treatment has lower costs and better outcome; \*On CSDD higher scores worse outcome; therefore negative incremental CSDD scores indicate better outcome for active treatment. In case of the comparison between mirtazapine and sertraline this is mirtazapine; \*\*patient rated

**Cost-effectiveness**

As noted earlier, the primary economic evaluation was a cost-effectiveness analysis with CSDD as the outcome over, first, the period 0-13 weeks after randomisation, and second the period 0-39 weeks after randomisation. A secondary analysis was a cost-utility analysis using QALYs computed from the EQ-5D and societal weights over the same periods. Data used in the estimation of the ICERs are shown in Table 14. An ICER was calculated for each analysis comparing sertraline and mirtazapine against placebo and comparing mirtazapine against sertraline.

As reported previously, there were no significant differences in CSDD scores or QALYs in any of the pairwise comparisons between sertraline, mirtazapine and placebo. There were also no significant pairwise differences in costs from either perspective between the treatment groups.

Given uncertainty surrounding the choice of treatment when incremental costs are higher and incremental outcome better (or when incremental costs are lower and incremental outcome also lower), CEACs were used to aid decision-making. Probability estimates were plotted for a range of implicit monetary values attached to improvements in depression score and QALY gain. We are not aware of any studies that have attached monetary values to incremental changes in CSDD.

In Figure 5, we see that mirtazapine has a low probability (around 30%) of being more cost-effective than placebo if society was not willing to pay anything for a unit improvement in the CSDD depression score. The probability rose to 80% if society was willing to pay £5,000 for a unit improvement in CSDD score, and stays at 80% over values of willingness to pay for an improvement in CSDD score up to £30,000. Sertraline had a less than 20% chance of being cost-effective compared to placebo, with the probability increasing moderately to about 42% if society was willing to pay £5,000 for each point improvement in CSDD score; and stayed below 50% for willingness to pay values greater than £5000 and up to £30,000 for a point improvement in CSDD score.

When both active treatments – sertraline and mirtazapine - were compared against each other the likelihood that treatment with mirtazapine would be seen as more cost-effective than sertraline would be over 60% from a health and social care perspective (and over 90% from a health, social care and informal care costs perspective).

Figures 5 and 6 show the CEACs from the secondary economic evaluation, where costs were considered alongside QALYs. Although we found no significant differences in QALY gain in any of the pairwise comparisons between sertraline, mirtazapine and placebo, we see a trend towards marginally higher QALY gains (using the EQ-5D measured directly from patients) for the active treatments.

Figure 7 suggests that the probability that mirtazapine is more cost-effective than placebo was 89% and increased to over 90% for a willingness to pay of £30,000 for a QALY. The likelihood of sertraline being more cost-effective than placebo was just over 50% and rose to just over 70% over higher values of willingness to pay for a QALY. Figure 8 shows mirtazapine had a higher probability of being more cost-effective than sertraline (over a range of willingness to pay values from £0 to £30,000) when health and social care costs are considered on their own, and also when considering health, social care and informal care costs.

In addition to assessing the uncertainty surrounding the cost-effectiveness of the antidepressants, we also assessed uncertainty around parameter estimates included in the cost analysis. For the main analyses, informal care costs were based on hourly cost of a home care worker. This hourly value for the care-giving inputs by friends and family was replaced in sensitivity analysis by an opportunity cost estimate, calculated as the gross hourly wage of a carer in paid employment and zero for a carer not in paid employment. Using alternative values of caregiver time inputs did not alter the findings (Table 15).

**Figure 5 Probability treatment is cost effective – 0-39 week: Health, social care costs and depression score (CSDD)**

**Figure 6 Probability Mirtazapine is cost effective relative to Sertraline at 0-39 weeks: Costs and depression score (CSDD)**



**Figure 7 Probability treatment is cost effective relative to placebo: Health, social care and informal care costs and QALYs**



**Figure 8 Probability Mirtazapine is cost effective relative to Sertraline: Costs and QALYs**



**Table 16 Sensitivity analysis**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Placebo****Mean (sd)** | **Sertraline****Mean (sd)** | **Mirtazapine****Mean (sd)** | **Mean difference** **(Sertraline – Placebo)** **(95% CI)** | **Mean difference (Mirtazapine – Placebo)** **(95% CI)** | **Mean difference (Mirtazapine – Sertraline)** **(95% CI)** |
| Main analysis – 0-13 weeks(total cost including informal care) | 4182 (5821) | 4616 (6488) | 3818 (7060) | 434 (-1340 to 2356) | -365 (-2212 to 1560) | -798 (-2754 to 1498) |
|  (a) Applying gross wage for informal care inputs | 3368 (4769) | 3663 (5008) | 3592 (5461) | 322 (-1081 to 1797) | -353 (-1778 to 1087) | -71 (-1588 to 1588) |
| Main analysis – 0-39 weeks (total cost including informal care) | 5497 (7922) | 6202 (8241) | 4391 (5285) | 705 (-1855 to 3234) | -1106 (-3137 to 970) | -1811 (-4048 to 543) |
|  (a) Applying gross wage for informal care inputs  | 4476 (6512) | 5177 (6574) | 3830 (4777) | 702 (-1313 to 2751) | -645 (-2415 to 986) | -1347 (-3368 to 280) |

**CHAPTER 4: DISCUSSION**

This is a trial with negative findings but important clinical implications. The data suggest clearly that antidepressants, given with normal care, are not clinically effective when compared with placebo for the treatment of clinically significant depression in dementia. This implies a need to change the current clinical practice of prescribing antidepressants as the first line treatment of depression in dementia due to Alzheimer’s disease.

**Limitations**

First, the drop out will have introduced bias if those dropping out had a different response to the trial interventions or placebo compared with those completing the trial. However this was designed as a pragmatic trial with few exclusions to mirror closely real clinical populations, and the levels of disengagement are similar to those experienced in clinical settings. Strenuous efforts were made to follow up and obtain outcome data on all those randomised but who defaulted from either the trial compound or clinical services.

A second putative limitation is the revision during the trial of the target sample size. Because of slower than forecast recruitment, we sought an extension and therefore further funding. The funder ordered interim analyses to determine the numbers needed using the data available on 75 cases followed up at 13 weeks. The new target set was 339. We recruited 326, falling short of the new target by 13. Nevertheless, this is the largest ever RCT of depression in dementia with unequivocal findings showing no effect of either antidepressant compared with placebo. Had the pattern of change seen in those recruited been continued, the extra precision in estimates that would have come from either another 13 cases, or even achieving the original trial target of 507, would not have generated a statistically significant positive result for either antidepressant.

Third, measurement error caused by the effect of cognitive impairment on domains such as memory, language, and reasoning is a potential limitation. However the study included only those measures best validated for use in dementia. Our primary outcome, the CSDD, is the most robust available measure of depression in dementia60 incorporating data from the carer, the person with dementia, and the rater. Finally, we did not capture elements of intervention by the clinical teams other than the group to which they were randomised. Had we been able to characterise these non-drug elements of treatment then we might have been able to investigate their role in patient recovery. However there is no suggestion that these would have varied across the three groups, so again the results would not have changed.

Finally it might be considered a limitation that we did not adjust the results for the multiple comparisons made in the secondary analyses. The data are presented as they are so that the reader can interpret the actual findings as they find best. The work should be reviewed considering a 1% significance level for all secondaries.

**Generalisability**

This study was designed to reflect real clinical populations and interventions as closely as possible. To this end we minimised exclusions and had permissive inclusion criteria. However the findings may not generalise to those too critically ill to risk randomisation (chiefly those with high suicide risk). Only three potential participants were excluded on this criterion but there will have been more not referred into the trial. Equally, outcomes of those with depression but a CSDD score under 8 would not be covered by this study. In practice however very few people with a CSDD score at this level would be considered to have clinically significant depression, so the effect on generalisability will be limited.

One of the strengths of this study is its size and the broad nature of the study group, both by the range of depressive symptoms and the severity of dementia, neither of which appeared to influence outcomes. We included not only those with narrowly defined Alzheimer’s disease but also those with probable and possible Alzheimer’s disease. This is closer to the population encountered in clinical practice where there is often mixed dementia (ie those with a vascular component to their dementia). However prudence would limit generalisability to Alzheimer’s disease and mixed dementia only and not to other subtypes such as vascular dementia, dementia with Lewy bodies or fronto-temporal dementia.

The one major limit to generalisability comes from all cases being drawn from referrals to old age psychiatry services. Such services are designed to deal with complex clinical situations, but there will be instances where people with depression in dementia are not referred to specialist services but remain either treated or untreated in primary care. Possibly, such cases would respond differently to antidepressants. However, finding unrecognised and untreated cases in primary care is difficult and referral of such cases to specialist services is good practice. Given the participants were not drawn from specialist research clinics or tertiary care, but from nine geographically diverse areas and a large number of clinicians representative of services in general (please see acknowledgements), the external validity of the results reported here will be maximised.

The drugs used in this study represent the two most used classes of antidepressants but the extent to whether other classes (eg dual-acting antidepressants like venlafaxine) might have an effect is unclear; it would however be reasonable to expect broadly similar responses in drugs of the same general class.

**Interpretation**

The main message from this study is that the drugs from the two classes of antidepressants most likely to be prescribed for depression in Alzheimer’s disease appear to be no more effective than placebo. This negative finding does not seem attributable to the type or the severity of depression in dementia included, or to the severity and vascularity of the dementia included. In this our results are in line with those of the DIADS-II study.28,29 It is however encouraging for people with depression in dementia that there was a strong consistent pattern of improvement in the depression at three and nine month follow up for this group of people referred to old age psychiatric services. This study gives strong evidence that this improvement is not attributable to antidepressants. What this study cannot tell us is if this improvement is a function of the non-drug “treatment as usual” by these old age psychiatric services, or due to artefact such as regression to the mean, the Hawthorne effect, or part of the natural history of depression in dementia. The last is perhaps made less likely by the finding that 221/326 (68%) had been depressed for more than six months prior to randomisation.

In terms of harms from medication, there were more adverse reactions in those treated with antidepressants compared with placebo as in other studies.28,29 It is important to be cautious about drawing conclusions from the analyses of secondary outcomes; the key message remains that there is no positive effect of the antidepressants on any of the pre-specified comparisons compared with placebo. There is however a signal in the data consistent with the pattern of adverse reactions observed. There were fewer neuropsychiatric symptoms, higher carer-rated participant quality of life, and higher carer quality of life in those treated with mirtazapine compared with sertraline. Also, carers of those receiving placebo had higher quality of life themselves and better mental health compared with those caring for people on sertraline. Taken together, even though these differences did not persist at 39 week follow-up, they may suggest that sertraline has more negative impacts than mirtazapine. This is of clinical importance since it is common clinical practice to use sertraline following the positive results of the first DIADS study.26

One of the unique elements of this study is the simultaneous evaluation of cost effectiveness as well as clinical effectiveness. As far as we are aware, this is the first randomised controlled trial with an economic evaluation of the use of pharmacotherapy for older people with dementia and depression. Because of the lack of significant pairwise differences in costs or outcomes (CSDD score) between sertraline, mirtazapine and placebo, the active treatments mirtazapine and sertraline have a low probability of being cost-effective compared to placebo. However it is interesting that when both active treatments are compared against each other, treatment with mirtazapine has a high probability of being cost effective compared with sertraline.

Care professionals, policy makers and people with dementia and their families are primarily interested in quality of life, and so a secondary cost-effectiveness analysis examined pairwise cost differences between the three treatments relative to the incremental difference in QALY gain. There were non-significant pairwise differences in costs or outcomes (QALY gains) between sertraline, mirtazapine and placebo. Sertraline had a low probability of being cost-effective compared to placebo. However; treatment with mirtazapine had a high probability of being cost-effective compared to placebo or when compared against sertraline.

This seems counter-intuitive given the lack of clinical effectiveness demonstrated in the primary analyses. We considered possible reasons for this finding: first, there was a trend towards lower incremental costs and higher incremental QALY gains for mirtazapine when compared to sertraline and placebo in turn. The trends observed towards lower costs were due to the significantly lower informal care inputs when with patients treated with mirtazapine compared with those treated with placebo or sertraline. The differences in improvements in quality of life could perhaps be explained in part by the effects of treatment with mirtazapine such as amelioration of sleep disturbances or anxiety state not explored in this study.61,62 Improvements in sleep could potentially enhance mood not captured by the CSDD and mood has been shown to be correlated with patient-reported EQ-5D scores.63 In this way mirtazapine might have a more general effect that was beneficial for both the patient and the carer.

When looking at our secondary outcomes (such as quality of life and NPI) it may well be that the amendments to protocol in terms of sample size resulted in a loss of power for secondary analyses. As discussed above, during the study, the protocol needed to be amended after slower than expected recruitment. An interim analysis was completed of the primary outcome and the sample size was recalculated based on the estimates from the interim analysis. The variance in these CSDD scores was smaller than previously expected. So under the new calculation (of a smaller sample size), there was enough power to show the potential differences in the CSDD, but there was no such analyses for the secondary outcomes. The study may therefore not have been sufficiently powered to test the patterns of response observed in the secondary outcomes.

In any case it is striking that in the long run those randomised to mirtazapine appear to use half as much carer time as those randomised to sertraline or placebo. Likewise the pattern of dominance of mirtazapine over sertraline is maintained in these analyses. All providing further evidence that sertraline may not be a good choice for the treatment of depression in dementia. The extent to which this is generalizable to other SSRIs is not clear from our study. The potential positive effects of mirtazapine seem more general than specific and may act more in the realm of general behavioural and psychological symptoms in dementia (BPSD) than depression per se. It is possible for example that a positive effect on sleep or agitation in the person with dementia may result in relief, not only for the person with dementia but also the carer in terms of hours of care needed.

The development of BPSD (eg agitation, aggression, wandering, shouting, repeated questioning, depression and sleep disturbance) is common in dementia occurring at some stage in up to 90% of cases. They cause problems in themselves, which complicate care, and they can occur at any stage of the illness. They are a legitimate object for intervention to decrease distress and harm, and increase quality of life for the person with dementia and their carers. One area for concern is the reflexive use of antipsychotics to treat these symptoms. A ministerial enquiry into the use of antipsychotic drugs in dementia concluded that “…current systems appear to deliver a largely antipsychotic-based response”.64 It is clear that these medications are being prescribed to deal with behavioural and psychological symptoms in dementia rather than just for psychosis.

The evidence includes gaps, contradictions and complexity but there is emerging consensus with respect to the level of use and risk of antipsychotic drugs for people with dementia. Reviewing the evidence, these drugs appear to have only a limited positive effect in treating these symptoms but can cause significant harm to people with dementia. On balance, it appears that around 180,000 people with dementia are treated with antipsychotic medication across the country per year. Of these, up to 36,000 may derive some benefit from the treatment. In terms of negative effects that are directly attributable to the use of antipsychotic medication, use at this level equates to an additional 1,800 deaths, and an additional 1,620 cerebrovascular adverse events, around half of which may be severe, per year.64

Despite the limited evidence base, the use of non-pharmacological interventions as the first-line treatment for BPSD reflects 'best practice' when taking into account safety considerations and the high rates of resolution of symptoms with placebo in pharmacological trials.34 The main reason for the widespread use of antipsychotics is the limited evidence for alternative treatments. Other pharmacological treatments used include anticonvulsants (carbamazepine and sodium valproate), and antidepressants (trazadone and citalopram). The best evidence is for carbamazepine, which has been shown to be better than placebo for agitation in several small placebo-controlled trials,65 but there is limited information about long-term safety in people with dementia. A recent meta-analysis concluded that sodium valproate was only effective at high doses that were associated with unacceptable side effects.66 The results of double-blind placebo-controlled trials of trazadone have been disappointing.67

In a double-blind placebo-controlled trial of people with AD that predominantly focused on depression, citalopram was also associated with improvement in a number of other behavioural and psychiatric symptoms, including irritability and restlessness.68 However, as neuropsychiatric symptoms were not the main focus of the study, only a modest proportion of participants had clinically significant behavioural and psychiatric symptoms at baseline so the results are difficult to interpret. In a definitive trial of a cholinesterase inhibitor for the treatment of clinically significant agitation in people with AD, donepezil showed no advantage over placebo.69 One recent re-analysis of a placebo-controlled trial of memantine in people with moderate to severe AD suggested that patients with neuropsychiatric symptoms benefited from treatment.70

The data presented here suggest that there may well be value in conducting an RCT of mirtazapine for the treatment of BPSD; no such trial has ever been completed. One small scale open label pilot studies gives supportive evidence for the potential of a trial in this area (those on mirtazapine did better).71 Given the paucity of alternatives and the priority of finding safe and effective treatments for BPSD, these data suggest that a placebo-controlled trial of mirtazapine would be of value.

**CHAPTER 5: CONCLUSIONS**

**Implications for health care**

So what can be concluded? This study finds no evidence to support the use of antidepressants as as a first line treatment for people with depression in Alzheimer’s disease who are referred to old age psychiatry services as many cases will resolve with usual care and without sertraline or mirtazapine. An important exclusion to this are the most critical of cases (by reason for example of self-harm or other risk) which were not included in this study.

Stepped care, with ‘watchful waiting’ is advocated currently for the general treatment of depression (without dementia) in the community. The first step is provision of “low-intensity psychosocial interventions” with more complex psychosocial interventions an alternative to antidepressants at the next stage of severity.72  Those recruited into the trial will have received non-drug ‘treatment as usual’ provided by the community mental health teams to whom they were referred. This will have included a broad range of supportive and problem-solving interventions, commonly delivered by a community psychiatric nurse, often in their own household. This will have focussed on problems encountered by the person with dementia and the carer, covering aspects of dementia as well depression and ranging in intensity from low to high as needed. Identifying which components of ‘usual care’ may be effective is an important area for future research. Compared with this personalised care the Hawthorne effect of the study assessments is likely to have had only a minor impact. These data suggest that having depression in dementia may be an appropriate trigger for referral to specialist services where non-drug treatments can be deployed, perhaps avoiding the use of medication with potential for adverse reactions.

In summary, the practical implications of this study are that we should reframe the way we think about the treatment of people with dementia who are depressed, the evidence does not support the routine prescription of antidepressants for depression in dementia. As we find no evidence to support use of antidepressants, it suggests that potential cases might be more appropriately managed by specialist services that are able to offer non-drug interventions for depression and case management that may not be available in primary care. Based on the data (a decrease at 13 weeks and this then maintained), save for those in whom medication is indicated by risk or extreme severity, In the absence of evidence to the contrary it might be appropriate to reconsider antidepressant prescribing for those who have not responded within a three month period (Figure 9).

***Figure 9: management of depression in dementia***

**Recommendations for research**

1. The secondary analyses presented here suggest that there would be value in carrying out a placebo controlled trial of the clinical and cost effectiveness of mirtazapine in the management of BPSD.

2. A conclusion from this study is that it remains both ethical and essential for trials of new medication for depression in dementia to have a placebo arm.

3. Further research is required to evaluate the impact that treatments for depression in people with dementia can have on their carers, not only in terms of any impacts on their quality of life but also the time they spend care-giving.

4. There is a need for research into alternative biological and psychological therapies for depression in dementia. These could include evaluations of new classes of antidepressants (such as venlafaxine) or anti-dementia medication (eg cholinesterase inhibitors).

5. Research is needed to investigate the natural history of depression in dementia in the community when cases are not referred to secondary care services.

5. Further work is needed to investigate the cost modelling results in this rich dataset, investigating carer burden and possible moderators to the treatment effects.

6. There is scope for re-analysis of the primary outcome in terms of carer and participant CSDD results.

**CHAPTER 6: ACKNOWLEDGEMENTS**

**Contributors**

SB was the chief investigator for the study and designed and managed the study with input from the group. JH and MD did the statistical analyses. All authors participated in data interpretation. SB drafted the first and subsequent versions of this report with input and key revisions by all authors, who reviewed and approved the final submitted report.

**HTA-SADD recruitment group (in addition to the authors)**

*Birmingham* Abdul Patel, Chris Vasillas, George Tadros, Martin Curtice, Alison Taylor, Avtar Singh Dhariwal, Seng E Goh, Deepak Kumar Shukla, William John Creaney, Rafi Arif, Karim Saad, Lucy Caswell, Bart Sheehan, and Pravir Sharma;

*Cambridge* Carol Gregory, Rob Butler, Ehab Hegazi, and Shamim Osmani Ruhi;

*Leicester* Ann Boyle, Ban Al-Kaissy, and Saminathan Anand;

*Liverpool* Lisa Beddoes, Tafika Chowdhury, Mavis Evans, Sumanth Kumar, Javier de Arcaute, Peter Metcalfe, Jane Devaney, Andrew Chatfi eld, Ashley Baldwin, Sudip Sikdar, Jukanti Raju, Frances Lindon, Mark Theophanous, John Glyn Thomas, Maryyum Hussain, Miranda Conway, and Emad Salib;

*Manchester* Sean Lennon, Harry Allen;

*Newcastle* Andrew Teodorczuk, Akshya Vasudev, Jonathan Richardson, John-Paul Taylor, Jane Newby, Mani Santhanakrishnan, Rod Gallagher, Julian Hughes, Adedayo Sobowale, Darren Craddock, Frances Dobie, Peter Howorth, Rory O’Shea, Apsara Panikkar, Anitha Howard, and Richard Harrison;

*North London* Robert Tobiansky, Vincent Kirchner, Elizabeth Sampson, Anthony Katz, Lucy Watkin, Theofanis Vorvolakos, Jegathesvary Thirunathan, Hilary Kinsler, Shakil Khawaja,Andrew Winnet, Mohan Bhat, Amod Dalvi, Rajeeva Abeysuriya, Zuzana Walker, Beverly Louis, Gareth O’Leary, Simon Adelman, Pushpa Naveenan, and Domi Gnanenthiran;

*Southampton* Vicky Banks, Karen Cotton, Janet Daoud, Valerie Hall, and June Salkeld; and

*South London and Kent* Patricia Irogeme, Tim Helme, John Besson, Naheed S Khan, Jenifer Chan, Kompancariel K Kuruvilla, Ananth Puranik, Carl Beckley, Justin Sauer, and Suki Greaves.

*Research workers and Mental Health Research Network and Dementias and Neurodegenerative Diseases Research Network clinical study officers:*

*Birmingham* Analisa Smythe, Jan Wright, Divya Chadha, Mohammed Shabbir, and Siobhan Keogh;

*Cambridge* Angela Lynch, Kathryn Betts, Jane Addison, Fiona McDougal, Angela Browne, Regina Mello-Barreto, and Freya Mellor; *Leicester* Sarah Baillon, Penny Wakefi eld, Alex Satchwell, Anne Chafer, Tracy McCranor, Rumun Sandhu, and Shaukat Desai;

*Liverpool* Lisa Douglas, Helen Newell, Samantha Fitzpatrick, Rachel Whalley, Leann Westmoreland, Maggie Lo, Caroline Mogan, and

Helen Beaumont-Kellner;

*Manchester* Jacqueline Crowther, Stephen Chew-Graham, Octavia Smart, Emma Oughton, Jonathan Bowker, Katrina Wade, Ann Morrow, Gemma Woods, Helen Williams, Maria Kaltsi, Magdalen Fiddler, Nichola Verstraelen, Rebecca Rowles, and Lindsey Copeland;

*Newcastle* June Pearson,Jill Davison, Suzanne Humphrey, Joshua Wood, Saffra Knox, Jessica McClosky, Katherine Richardson, Karen Anne Morgan, and Vanessa Waggott;

*North London* Ryan Li, Sharmila Logathas, Stephanie Habermann, Kofi Kramo, Shilpa Bavishi, Patricia Ndhlovu, Sarah Dickens, Khodayar Shahriyarmolki, Emily Dixon, Maria Sampson,Gemma Hardy, and Bertha Mangunda;

*Southampton* Christine Dean, Annette Stevens, Laura Wolfe;

*South London and Kent* Michaela Poppe, Thandiwe Mtendera, Gaby Illingworth, Susan Thompson, Mohamed Pujeh, and Alex Quigley.

*Mental Health & Neurosciences Clinical Trials Unit:* Joanna Kelly, Caroline Murphy, Clare Rutterford, and Rajesh Shah.

**Conflicts of interest**

SB, MD, CB, RB, PB, CF, CH, CK, MK, CL, JL, GL, EM-C, JM, MO, JO’B, AT, KW, and AB have received consultancy fees, speakers’ fees, research funding, or educational support to attend conferences from pharmaceutical companies involved in the manufacture of antidepressants and anti-dementia drugs. SB and AB have been employed by the Department of Health for England and CB has been employed by the Alzheimer’s Society. JH, RR, NMcC, SN, MP, and RW declare that they have no conflicts of interest.

**Acknowledgments**

This project was funded by the UK National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (project number 04/11/02). The views and opinions expressed here are those of the authors and do not necessarily reflect those of the HTA programme, NIHR, National Health Service, or the Department of Health. We thank all the participants and carers that gave their time to be part of this study; Georgina Charlesworth, Tom Dening, and David Wilkinson for invaluable scientific advice, support, and input into the project at key stages from planning onwards; Pfizer for their donation of the sertraline and sertraline placebo for this trial; members of the HTA-SADD data monitoring and ethics committee and the HTA-SADD trial steering committee (Peter Connelly [chair DMEC], Robin Jacoby [chair TSC], Rowan Harwood, Cornelius Kelly, Angela Clayton-Turner, Craig Ritchie, and Ed Juszczak); the Alzheimer’s Society for providing patient and public involvement support into the study; the NIHR Mental Health Research Network (MHRN) and Dementia and Neurodegenerative Disease Research Network (DeNDRoN) for practical help; and referring clinicians in every area.

**CHAPTER 7: REFERENCES**

1. Hofman A, Rocca WA, Brayne C et al (1991). The prevalence of dementia in Europe. *Int J Epid* 1991, 20, 736-48.

2. Launer LJ, Brayne C, Dartigues J-F et al. Epilogue. (1992) *Neuroepidemiology* 1992, 11 (suppl 1), 119-121.

3. Prince M, Jackson J. *World Alzheimer’s Report 2009*. London: Alzheimer’s Disease International 2009.

4. Knapp M, Prince, M, Albanese E, Banerjee S, Dhanasiri S, et al. *Dementia UK: the full report*. London: Alzheimer's Society 2007.

5. Lowin A, Knapp M, McCrone P (2001). Alzheimer's disease in the UK: comparative evidence on cost of illness and volume of research funding. *Int J Geriatr Psychiatry* 2001*,* 16:1143-8.

6. Wimo A, Prince M. World Alzheimer’s Report 2010: the globaleconomic impact of dementia. London, UK: Alzheimer’s Disease International, 2010

7. Prince M, Jackson J. World Alzheimer’s Report 2009. London, UK: Alzheimer’s Disease International, 2009.

8. Department of Health (2001). *National Service Framework for Older People.* London: DH 2001*.*

9. DH (2005). *Everybody’s Business*. London: CSIP 2005.

10. Department of Health. Living well with dementia, a national dementia strategy. London, UK: Stationery Office, 2008.

11. NAO. National Audit Office Report. Improving Services and Support for People with Dementia HC 604, Report by the Comptroller and Auditor General, Session 2006-2007, TSO: London 2007.

12. Murray J, Schneider J, Banerjee S *et al* (1999). EUROCARE a cross-national study of co-resident spouse carers for people with Alzheimer's dementia II: a qualitative analysis of the experience of caregiving. *Int J Geriatr Psych* 1999, 14, 665-661.

13. Schneider J, Murray J, Banerjee S, et al (1999). EUROCARE: a cross national study of co-resident spouse carers for people with Alzheimer's Disease I - factors associated with carer burden.  *Int J Geriatr Psych* 1999*,* 14, 665-661.

14. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer’s disease III: Disorders of mood. *Br J Psychiatr*, **157**: 81–86 1990.

15. Ballard CG, Bannister C, Oyebode F. Depression in Dementia Sufferers - A Review.  *Int J Geriatr Psychiatr*; **11**: 507–515 1996.

16. Burns A. Affective symptoms in Alzheimer’s Disease  *Int J Geriatr Psychiatr*; **6**: 371–376 1991.

17. Greenwald BS, Kramer-Ginsberg E, Marin DB et al. Dementia with coexistent major depression. *Am J Psychiatr*. **146**: 1472–8 1989.

18. Ballard CG, Bannister C, Oyebode F. Depression in Dementia Sufferers - A Review.  *Int J Geriatr Psychiatr*; 11: 507–515 1996.

19. Bains J. Birks JS. Dening TR. The efficacy of antidepressants in the treatment of depression in dementia. Cochrane Database of Systematic Reviews 2002.

20. Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. *J Am Geriatr Soc* 2011; 49: 577–85.

21. Modrego PJ. **Depression in Alzheimer’s Disease. Pathophysiology, Diagnosis, and Treatment. *J Alzheimers Dis*, 21,** 1077-1087 2010.

22. Thompson S, Herrmann N, Rapoport MJ, Lanctôt KL. Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis. *Can J Psychiatry*. 52: 248-55. 2007.

23. Petracca G, Teson A, Chemerinski E, Leiguarda R, Starkstein SE. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. *J Neuropsychiatr Clin Neurosci*, **8**: 270-5 1996.

24. Reifler BV, Teri L, Raskind M et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression (1989). *Am J Psychiatry*, **146**: 45-9 1989.

25. Lyketsos C, Sheppard J, Steele C et al. A randomized placebo-controlled, double-blind, clinical trial of sertraline in the treatment of depression complicating Alzheimer’s Disease. *Am J Psychiatry*, **157**, 1686-89 2000.

26. Lyketsos CG, DelCampo L, Steinberg M et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. *Arch Gen Psychiatry***, 60**: 737-46 2003.

27. Alexopoulos GS, Abrams RC, Young RC *et al*. Cornell scale for depression in dementia. *Biological Psychiatry*, **23**, 271-284 1988.

28. Rosenberg PB, Drye LT, Martin BK et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010; 18: 136-45.

29. Weintraub D, Rosenberg PB, Drye LT, et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010, 8: 332-40.

30. Greenwald BS. Kramer-Ginsberg E. Marin DB. Laitman LB. Hermann CK. Mohs RC. Davis KL. Dementia with coexistent major depression. *American Journal of Psychiatry*. 1989, **146**:1472-8.

31. Anonymous. Do SSRIs cause gastrointestinal bleeding? Drugs and Therapeutics Bulletin, 2004; 42(3), 17-18.

32. Doody R, Stevens J, Beck C et al. Practice parameter: management of dementia (an evidence based review). *Neurology*, **56**, 1156-66 2000.

33. Eccles M, Clarke J, Livingston M, Freemantle M, Mason J. North of England evidence based guidelines development project: guideline for the primary care management of dementia. *Brit Med J*, **317**, 802-808 1998.

34. NICE/SCIE. *Dementia: supporting people with dementia and their carers in health and social care*. London: Department of Health 2006.

35. Ensrud KE. Blackwell TL. Mangione CM. Bowman PJ. Whooley MA. Bauer DC. Schwartz AV. Hanlon JT. Nevitt MC. Study of Osteoporotic Fractures Research Group. Central nervous system-active medications and risk for falls in older women. *Journal of the American Geriatrics Society,* 2002; **50(10)**:1629-37.

36. Nyth A, Gottfries C, Luby K et al. (stahlA controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without dementia. *Acta Psychiatr Scand*, 1991; **86**, 138-45.

37. Stahl SM. Entsuah R. Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. *Biological Psychiatry*, 2002; **52**:1166-74.

38. Oslin D, Ten Have T, Streim J et al. Probing the safety of medications in the frail elderly: evidence from a randomized controlled clinical trial of sertraline and venlafaxine in depressed nursing home residents.  *J Clin Psychiatry*, 2003; **64**, 875-882.

39. Banerjee S. Services for older adults. In: *Textbook of Community Psychiatry* (eds Thornicroft G, Smuzkler G). Oxford University Press: London. 2001; 81-396.

40. Ballard CG, Patel A, Solis M, Lowe K, Wilcock G. A One Year Follow up Study of Depression in Dementia Sufferers. *Br J Psychiatry*; 1996; **68**:287-291

41. Ballard CG. O'Brien JT. Swann AG. Thompson P. Neill D. McKeith IG. The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: persistence and new cases over 1 year of follow-up. *Journal of Clinical Psychiatry*;2001; **62**:46-

42. Ballard C, O'Brien J, Swann A, Fossey J, Lana M. A One Year Follow-up study of behavioural and psychological symptoms in dementia (BPSD) amongst people in care environments. *J Clin Psychiatry*; 2001; **62**: 631-636

43. Teri L. Gibbons LE. McCurry SM. Logsdon RG. Buchner DM. Barlow WE. Kukull WA. LaCroix AZ. McCormick W. Larson EB. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. *JAMA,* 2003; **290**:2015-22.

44. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer’s Disease: report of the NINCDS-ADRDA work group.  *Neurology*, **34**, 939-44 1984.

45. Netten A. Costing informal care. In Netten A and Beecham J (eds) *Costing community care: theory and practice*. Ashgate: Aldershot 1993.

46. Smith SC, Lamping DL, Banerjee S et al. Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. 2006; *Psychol Med*, **37**: 737-746.

47. The EuroQoL Group. EuroQoL-a new facility for the measurement of health-related quality of life. *Health Policy*;1990 **16**: 199-208.

48. Folstein MF, Folstein SE, Mc Hugh PR. Mini Mental State*. J Psychiatric Res*, 1975, **12**, 189-198.

49. Goldberg D, Williams P. *A user’s guide to the General Health Questionnaire*. Windsor: NFER-NELSON 1988.

50. Ware JE, Kosinski M, and Keller SD. A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. *Medical Care*, 1996 **34**: 220-233.

51. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. *The Gerontologist*, 1980 **20**, 649-655.

52. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. *Neurology* 1994; 44: 2308-2314.

53. Rosen WG, Terry RD, Fuld PA, et al. Pathologic verification of ischemic score in differentiation of Dementias. *Ann Neurol* 1980:7:487.

54. Beecham J. & Knapp M. Costing Psychiatric Interventions. In: *Measuring Health Needs*, 2nd edn (ed. G. Thornicroft), pp. 200–24. 2001; Gaskell, London.

55. Curtis L. Unit Costs of Health and Social Care. 2010; PSSRU, University of Kent.

56. Department of Health. National Health Service Schedule of Reference Costs 2010. http://www.doh.gov.uk/nhsexec/refcosts.htm [accessed May 2010]

57. British Medical Association and Royal Pharmaceutical Society of Great Britain. *British National Formulary 59 (March)*. 2010; BMA, RPS, London.

58. Curtis L. Unit Costs of Health and Social Care. 2007, PSSRU, University of Kent.

59. Olin JT, Katz IR, Meyers BS, Schneider LS, Lebowitz BD. Provisional diagnostic criteria for depression of Alzheimer Disease. *American Journal of Geriatric Psychiatry*, 2002; **10,** 129-141.

60. E. Moniz-Cook; M. Vernooij-Dassen; R. Woodset al.  A European consensus on outcome measures for psychosocial intervention research in dementia care. *Aging and Mental Health* 2008, **12**, 14-29.

61. Schittecatte M, Dumont F, Machowski R, Cornil C, Lavergne F, Wilmotte J. Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology. 2002;46(4):197-201.

62. Muehlbacher M, Nickel MK, Nickel C, Kettler C, Lahmann C, Pedrosa Gil F, Leiberich PK, Rother N, Bachler E, Fartacek R, Kaplan P, Tritt K, Mitterlehner F, Anvar J, Rother WK, Loew TH, Egger C. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2005 Dec;25(6):580-3.

63. Naglie G, Tomlinson G, Tansey C, Irvine J, Ritvo P, Black SE, Freedman M, Silberfeld M, Krahn M. Utility-based Quality of Life measures in Alzheimer's disease. Qual Life Res. 2006 May;15(4):631-43.

64. Banerjee S (2009). *Use of antipsychotics for people with dementia – time for action*. London: DH.

65. Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, Irvine C. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998 Jan;155(1):54-61.

66. Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD003945.

# 67. Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, et al Alzheimer's Disease Cooperative Study. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000 Nov 14;55(9):1271-8.

68. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry. 1990 Dec;157:894-901.

69. Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, et al CALM-AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med. 2007 Oct 4;357(14):1382-92.

70. Gauthier S, Wirth Y, Möbius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry. 2005 May;20(5):459-64.

71. Cakir S, Kulaksizoglu IB. The efficacy of mirtazapine in agitated patients with Alzheimer's disease: A 12-week open-label pilot study. Neuropsychiatr Dis Treat. 2008 Oct;4(5):963-6.

72. National Institute for Health and Clinical Excellence. *Depression – The treatment and management of depression in adults*. London: DH 2009.

**Appendix – Trial protocol**